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SUMMARY: 
 
For effective control of visceral leishmaniasis (VL) in East Africa, new rapid 
diagnostic tests are required to replace current tests with low sensitivity. The 
aim of this study was to improve diagnosis of VL in East Africa by testing new 
antigens from an autochthonous Leishmania donovani strain.  
 
 
 
 
We cloned and expressed a new antigenic protein (designated rKLO8) of 
Leishmania donovani containing putative conserved domains of significant 
similarity with immunodominant kinesin proteins of several Leishmania 
strains. rKLO8 exhibited 93% amino acid identity with cloned kinesin proteins 
of Leishmania infantum (rK39) and 88% with Leishmania donovani (rKE16). 
Sequence analysis of rKLO8, rK39 and rKE16 revealed genetic heterogeneity 
within immunodominant epitopes of these antigens. 
 
 
 
 
Immunoreactivity of the purified recombinant protein rKLO8 was confirmed by 
Western blot and enzyme-linked immunosorbent assay (ELISA). Importantly, 
antibody reactivity against rKLO8 was detected in VL patients but not in 
healthy controls. We successfully developed a diagnostic ELISA based on 
rKLO8 which was evaluated with sera from VL patients originated from 
Sudan, India and France. Direct comparison between rKLO8– and rK39 
ELISA revealed that our newly developed test system showed similar 
reactivity with sera of VL patients from France but increased with sera from 
Sudanese and Indian patients.  
 
 
 
 
Next, we compared the diagnostic performance of rKLO8- and rK39 ELISA 
with other commercially available tests, including rK39- and rKE16 rapid tests 
and direct agglutination test (DAT).  Results showed that all tests performed 
very well in India but best sensitivity in all countries was observed with 
rKLO8- and rK39 ELISA.  However in Sudan and France, the two rapid tests 
showed low sensitivity. DAT showed better sensitivity in Sudan and India than 
in France. The sensitivity of all tests was markedly reduced in VL patients co-
infected with human immunodeficiency virus (HIV). Furthermore, the rKLO8 
ELISA was also evaluated with sera of Leishmania-infected dogs from 
Portugal, Croatia and Brazil. The results showed that rKLO8 ELISA was 
  X 
similar to DAT but more sensitive than the routinely used immunofluorescent 
antibody test (IFAT).  
 
 
 
 
Thus, increased reactivity of sera from Sudanese VL patients with rKLO8 
shows that this antigen is a potential candidate for improving VL diagnosis in 
Sudan and other regions of East Africa where similar strains of Leishmania 
donovani are endemic.  
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ZUSAMMENFASSUNG: 
 
Die effiziente Kontrolle der viszeralen Leishmaniose (VL) in Ostafrika hängt ganz 
besonders von einer schnellen und sensitiven Diagnostik ab. Gegenwärtige 
Testsysteme sind für die Diagnostik der VL im Sudan leider nicht besonders gut 
geeignet. Ziel dieses Projektes war die Identifikation und Testung neuer Antigene 
eines aus dem Sudan stammenden Leishmania donovani-Stammes zur 
Verbesserung der VL-Diagnose in Ostafrika.  
 
 
 
 
Es wurde ein neues Antigen aus Leishmania donovani identifiziert und kloniert 
(rKLO8), das eine hohe Sequenzübereinstimmung mit dem immundominaten 
Kinesinprotein verschiedener Leishmania-Stämme aufweist. Die Immun-
reaktivität des aufgereinigten rekombinanten Proteins wurde durch Westernblot 
und ELISA getestet und bestätigt. Es zeigte sich, dass rKLO8 nur mit Seren von  
VL- Patienten, nicht jedoch gesunden Individuen reagiert.  
 
 
 
 
Zusätzlich wurde ein auf dem rKLO8-Protein basierter Test (ELISA) etabliert und 
mit Patientenseren aus dem Sudan, Indien und Frankreich evaluiert. Eine  
vergleichende Studie zeigte, dass das diagnostische Potential des neu 
entwickelten rKLO8 Tests im Sudan und Indien gegenüber dem derzeit 
verwendeten Testantigen, rK39, deutlich besser ist.  
 
 
 
 
Weiterhin wurde das diagnostische Potential der rKLO8 - und rK39 ELISA mit 
verschiedenen kommerziellen Tests, den rK39- und rKE16-Schnelltests und dem 
direkten Agglutinationstest (DAT) verglichen. Alle Tests zeigten bei Patienten aus 
Indien ähnlich gute Ergebnisse, bei VL-Patienten aus anderen Ländern jedoch 
zeigten der rKLO8- und rK39-ELISA die höchste Sensitivität.  
Ein weiterer Befund war, dass die Koinfektion mit dem HI-Virus die Sensitivität 
aller Testsysteme beträchtlich reduzierte. 
 
 
 
 
Zuletzt wurde der neu entwickelte rKLO8-Test auch mit Seren VL-infizierter 
Hunde aus Portugal, Kroatien und Brasilien getestet. Der ELISA war in seiner 
diagnostischen Potenz ähnlich dem DAT, im Vergleich zum routinemäßig 
eingesetzten immunofluoreszenz-basierten Antikörpertest (IFAT) jedoch deutlich 
sensitiver. 
 
  XII 
Zusammengefasst stellt rKLO8 aufgrund seiner erhöhten Reaktivität mit 
Patientenseren aus dem Sudan ein potentielles Antigen dar, mit dem die VL- 
Diagnostik im Sudan und anderen Leishmania donovani endemischen Regionen 
Ostafrikas verbessert werden kann.  
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1. INTRODUCTION: 
 
1.1 General introduction:  
 
Leishmaniasis is a disease caused by protozoan parasites that belong to the 
genus Leishmania and is transmitted by the bite of phlebotomine sandfly vectors. 
It has world-wide distribution, affecting millions of people in 98 countries on 5 
continents with approximately 350 million people being under the risk (Desjeux, 
2004; Alvar et al., 2012). It is classified as one of the most neglected diseases 
because of the limited resources invested for the control of the disease (Yamey 
and Torreele, 2002).  
 
Leishmaniasis has three major clinical forms: cutaneous leishmaniasis (CL), 
mucocutaneous leishmaniasis (MCL) and visceral leishmaniasis (VL), the latter is 
the most severe form and is caused by various species of Leishmania (L.) 
donovani complex (Lainson and Shaw, 1987; Jamjoom et al., 2004). Of particular 
concern is the increase and expansion of VL in areas in East Africa that were 
previously non-endemic (Marlet et al., 2003; Alvar et al., 2007b). The mass 
population movement caused by the armed conflicts (e.g. Somalia) or peace (e.g. 
Sudan) let to increase exposure to sandfly vectors and contributed to increase 
geographical areas of the disease (Reithinger, et al., 2007). 
 
Sudan is one of the six VL-endemic countries that constitute 90% of global VL 
cases and has the highest incidence of post-kala-azar dermal leishmaniasis 
(PKDL) in the world (Ghalib and Modabber, 2007; Alvar et al., 2012). The country 
has experienced several outbreaks in the last two decades, the recent ones 
occurred between 2009 - 2011 in South Sudan (the new Republic of South 
Sudan) where more than 10,000 patients were reported (Doctors Without 
Borders, kala-azar home page, http://www.doctorswithoutborders.org/). The 
disease is further complicated by the spreading of HIV in VL-endemic areas. In 
Africa, the number of VL/HIV co-infections is increasing; approximately 30% of all 
VL patients in Ethiopia are also infected with HIV (Alvar et al., 2008).  
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1.2 History of leishmaniasis: 
 
Leishmaniasis was first reported in Jessore (now in Bangladesh) in 1824 during 
outbreak of fever that was thought to be due to malaria but failed to respond to 
quinine. In 1862, the disease spread to Burdwan in India, where it became 
epidemic. It is accepted that the Scottish pathologist, William Leishman and 
Professor Charles Donovan discovered the parasite in the spleen of an Indian 
patient in 1903 (see Cox, 2002). In early 1900s, leishmaniasis was reported in a 
Sudanese child who had come from Bahr el Gazal in South Sudan, which was the 
first reported case in East Africa (Neave, 1904). 
 
A full description of Leishmania in skin lesions was given by James Homer 
Wright, an American pathologist (Wright, 1903). However, David Cunningham 
might be the first who described the parasite in 1885 in specimen of skin lesion 
(see Write, 1903). The role of Phlebotomus sandflies in transmission of the 
infection to humans was experimental confirmed in 1921 by the Sergent brothers, 
Edouard and Etienne. In 1911, a Brazilian pathologist Gaspar Vianna showed 
that Leishmania in South America are different from those in Africa and India. His 
observation let to discovery of a new species, Leishmania braziliensis (see 
Cox, 2002).  
 
The origin of Leishmania parasites is not well understood. Recent studies have 
shown that Sudan might be the original focus of leishmaniasis; Leishmania 
donovani DNA was detected in bone marrow samples from ancient Nubian 
mummies from North Sudan dated back to around 4000 BC (Zink et al., 2006; 
Pratlong et al., 2001). Subsequently, the disease could have been introduced to 
the Indian subcontinent and the New World in early migrations (Ibrahim, 2002). 
Recent spreading of L. infantum from Southwest Europe to South America has 
occurred during European colonization of the New World, where the parasite was 
designated a distinct species name, Leishmania chagasi (Kuhls et al., 2011).  
 
1.3 Taxonomy of Leishmania: 
 
Historically, classification of Leishmania was based on eco-biological criteria such 
as sandfly species, geographical distribution, and clinical presentation of the 
disease. But these methods were insufficient and therefore other methods have 
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been used such as the patterns of polymorphism in kinetoplast DNA (kDNA), 
proteins or antigens. Leishmania and Viannia subgenera are separated based on 
their location in intestine of the sandfly; Leishmania develop within the midgut and 
foregut of the host while Viannia undergo an additional developmental phase 
within the hindgut. Other authors used isoenzyme analysis to define species 
complexes within the subgenera. Since 1970s, immunological, biochemical and 
genetic criteria are used for the current taxonomic classification (Fig. 1.1), which 
was developed by the World Health Organization (see Cupolillo et al., 2000; 
Banuls et al., 2007).  
 
Recently, a new taxonomic classification was introduced for the L. donovani 
complex including L. donovani, L. infantum, L. chagasi, and L. archibaldi, the 
causative agents of VL. Here all strains of L. donovani complex were 
phylogenetically grouped in two main clusters: L. donovani– strains from East 
Africa, India and Middle East; L. infantum– parasites from Europe, North Africa 
and Latin America. Therefore, L. donovani and L. infantum are considered the 
only recognized species within L. donovani complex. The degree of diversity 
among strains of L. chagasi and L. infantum is lower than that found within L. 
donovani strains (Mauricio et al., 2000; Lukes et al., 2007). 
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Fig. 1.1:  Classification of the genus Leishmania. The diagram shows the two 
subgenera and species of medical importance with their related diseases. Taxonomy is 
based on a scheme published by the World Health Organisation (WHO, 1990) with 
modification from the literature (Mauricio et al., 2000; Lukes et al., 2007; Bates, 2007). 
 
 
1.4 Clinical pictures of leishmaniasis in humans: 
 
Clinical symptoms of Leishmania infection in humans depend on parasite 
species and infected tissues, and represent a wide range of clinical 
manifestations (Fig. 1.2). After infection, many people remain asymptomatic for 
a certain time period, reflecting differences in parasite virulence and host 
population characteristics within the host (Chappuis et al., 2007). The most 
common forms of leishmaniasis in humans with their respective parasites are 
as follows:  
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1.4.1 Cutaneous leishmaniasis (CL):  
CL is the most common clinical form, which causes skin sores (ulcers) at the 
site of sandfly bite. It is mainly caused by L. amazonensis, L. braziliensis, L. 
guyanensis, L. mexicana, L. panamensis, L. naiffi, L. venezuelensis, L. lainsoni 
and L. shawi in the New World and L. major, L. aethiopica, L. tropica, L. arabica 
and L. gerbilli in the Old World. In Sudan, it is caused by L. major and L. tropica. 
However, other species such as L. donovani and L. infantum can also cause 
the disease (see Banuls et al., 2007). Few weeks after infection, patients 
develop skin ulcers in the exposed areas such as face, arms and legs, which 
usually heal within few months leaving scars. The disease may show different 
clinical manifestations in regard to the number of lesions and whether lesions 
are self-healing or require treatment (see Modabber et al., 2007).  
1.4.2 Mucocutaneous leishmaniasis (MCL):  
MCL is most common in Latin America. In contrast to CL, lesions lead to 
extensive destruction of the mucous membranes of the nose, mouth and throat 
cavity and surrounding tissues. MCL is mostly caused by L. braziliensis in 
Central and South America, but other species may also cause the disease, 
such as L. panamensis and L. guyanensis; in Ethiopia and Kenya it caused by 
L. aethiopica (see Banuls et al., 2007).  
1.4.3 Diffuse cutaneous leishmaniasis (DCL):  
DCL is a chronic form of the disease which occurs in individuals with impaired 
cell-mediated immune responses (Gaafar et al., 1995). It is characterized by 
non-ulcerating, non-necrotizing nodular lesions spread over the body that never 
heal spontaneously and tend to relapse after treatment, resembling 
lepromatous leprosy. It caused by L. aethiopica in Ethiopia and Kenya, L. major 
in Sudan and by L. amazonensis and L. braziliensis in Central and South 
America (see Zerpa et al., 2007).  
 
 
1- INTRODUCTION 
 6 
1.4.4 Visceral leishmaniasis (VL):  
VL (also known as kala-azar) is the most severe form of the disease with 100% 
mortality rate if not treated. It affects vital organs of the reticuloendothelial 
system such as spleen, liver, bone marrow, lymph nodes. VL is caused by 
species which belong to L. donovani complex that includes L. donovani in East 
Africa and the Indian subcontinent, L. infantum in Europe, North Africa and 
Latin America (Lainson and Shaw, 1987; Mauricio et al., 2000; Jamjoom et al., 
2004; Lukes et al., 2007). In most cases, patients develop the disease weeks to 
months after infection. Symptoms start with irregular fever, headache, 
sometimes with cough, abdominal pain, diarrhoea, vomiting, epistaxis and 
anaemia. Weeks later, patients lose weight and may show severe malnutrition. 
Signs include splenomegaly, hepatomegaly and/or lymphadenopathy, which is 
more frequent in Sudan than in other countries. Without treatment, patients may 
suffer from bacterial infection and severe anaemia (Jeronimo et al., 2007). 
However, co-infections with other pathogens such as Plasmodium species, 
Mycobacterium tuberculosis and HIV may give rise to atypical clinical pictures 
(de Beer et al., 1991; van den Bogaart et al., 2012). Other factors that may 
additionally complicate the infection is the occurrence of different Leishmania 
species or strains in the same host (Ibrahim et al., 1994; Martinez et al., 2002).  
 
 
 
Fig. 1.2: Clinical symptoms of leishmaniasis in humans: visceral leishmaniasis (VL), 
mucocutaneous leishmaniasis (MCL) and cutaneous leishmaniasis (CL). Adopted from: 
http://www.stanford.edu/group/parasites/ParaSites2007/ImmuneEvasion/. 
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1.4.5 Post-kala-azar dermal leishmaniasis (PKDL):  
PKDL is a skin condition that develops several months or years after successful 
VL treatment in individuals who are otherwise healthy (see Zijlstra et al., 2003). 
It occurs in 50% and 5-10% in treated VL patients in Sudan and India, 
respectively. However, it may also appear in individuals with no history of VL 
(Uranw et al., 2011). Typically, it starts on the face as papules which can 
spread to other parts of the body. It may increase in size to become macular, 
papular or nodular lesions in which the parasites can be detected (Fig. 1.3) 
(see Zijlstra et al., 2003).  
 
 
 
Fig. 1.3: Sudanese post-kala-azar dermal leishmaniasis (PKDL): From left to right: 
micropapular, papular and nodular lesions. Adopted from Zijlstra et al., (2003). 
 
 
1.5 Epidemiology and impact of leishmaniasis:  
 
Leishmaniasis has a world-wide distribution in areas ranging from rain forests to 
deserts, which cover some parts of the Old World (Africa, Asia, Europe) and the 
New World (the Americas). Approximately, 0.2 - 0.4 million visceral leishmaniasis 
(VL) cases and 0.7 - 1.2 million cutaneous leishmaniasis (CL) cases occur 
annually in 98 countries (Fig. 1.4 & 1.5). More than 90% of global VL cases occur 
only in six countries: India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia 
with approximately 20,000 – 40,000 deaths annually (Alvar et al., 2012). The 
disease affects both humans and animals with higher prevalence in poor rural 
communities than urban areas. Climate and economic changes are considered as 
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factors that affect the migration of people and expand the geographic range of the 
sandfly vectors (Desjeux, 2001; Reithinger, et al., 2007).  
 
VL in Asia is endemic in 6 countries: India, Bangladesh, Nepal, Bhutan, Sri Lanka 
and Thailand. This region is considered the biggest focus of VL in the world, with 
an estimated annual incidence of 162,100 – 313,600 (Alvar et al., 2012). The 
disease affects mainly poor people in rural areas; approximately 80% of all cases 
in the region come from the state of Bihar in India. There are approximately 200 
million people are at risk for VL in Indian subcontinent (Joshi et al., 2008).  
 
East Africa is the second major endemic region of VL in the world. The disease 
occurs either as sporadic severe outbreaks or as endemic disease (Ibrahim, 
2002). The seven countries where VL is endemic with high annual incidence are 
Sudan, Ethiopia, Kenya, Somalia, Uganda and Eritrea. Approximately, 29,400 – 
56,700 new cases occur each year (Alvar et al., 2012; Mueller et al., 2012).  
 
In Europe, VL is endemic in Mediterranean countries including Italy, France, 
Spain, Portugal, Greece, Croatia, Albania, Malta, Cyprus (see Schallig et al., 
2013), with an annual incidence of 1,200 – 2,000 (Alvar et al., 2012). The disease 
has spread also to neighbouring countries such as Bosnia and Herzegovina, 
Bulgaria, Hungary, Macedonia, Monaco, Romania, Azerbaijan, Georgia, 
Kazakhstan, Tajikistan, Turkey, Turkmenistan and Uzbekistan (WHO, 2004). Due 
to human-made environmental and global climate changes, the disease is 
thought to be increasing (Dujardin et al., 2008). In non-endemic countries of 
Europe, the majority of infections occur through travelling to endemic countries. 
However, reports indicate that VL is spreading in central Europe such as 
Germany where the disease was diagnosed in humans and dogs who had never 
been in known-endemic areas (Gothe, 1991; Bogdan et al., 2001; Mencke, 2011). 
In the New World, VL has been reported in several countries, covering parts of 
Southern USA, Mexico, North of Argentina, Brazil, Paraguay, Bolivia, Venezuela, 
Suriname, Guyana, Colombia, Honduras, Panama, Costa Rica, El Salvador, 
Guadeloupe, Guatemala and Nicaragua (see Kuhls et al., 2011). The annual 
incidence of VL throughout America is 4,500 – 6,800 (Alvar et al., 2012). Brazil is 
the country with the highest prevalence in this region, representing approximately 
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90% of the total cases (see Romero and Boelaert, 2010). In this country, the 
epidemiology of the disease is previously associated with migration to urban 
areas, causing several outbreaks in large cites (Albuquerque et al., 2009; Harhay 
et al., 2011). Until 1993, more than 90% of VL cases were reported in the north 
and north east of Brazil. However, in 2003 the disease spread to the south east 
and central west of the country. This increase was due to construction of a major 
road that allowed movement of people with their infected dogs to new areas (see 
Palatnik-de-Sousa and Day, 2011).  
CL is more widely distributed than VL, with about one-third of cases occurring in 
each of the three regions, America, Mediterranean area, and Asia. The ten 
countries with the highest numbers of CL cases are Afghanistan, Algeria, 
Colombia, Brazil, Iran, Syria, Ethiopia, Sudan, Costa Rica and Peru, together they 
account for 70% to 75% of the global estimated CL incidence (Alvar et al., 2012). 
In Sudan, most of the reported cases are from west and central regions where 
several outbreaks were reported: in Shendi‐ Atbara region (1976 ‐ 1977), in Tuti 
Island where approximately 10,000 cases were recorded (1985 – 1987) and 
along the Nile, north of Khartoum to the border with Egypt (Malaria Consortium, 
2010). 
 In some regions, outbreaks of CL are associated with armed conflicts and travel. 
In 2005, cases of CL were reported among International Security Assistance 
Force and the local population of Mazar-e Sharif, North Afghanistan (Faulde et 
al., 2008). In Syria, two years after the civil war started, an alarming increase in 
CL cases has been reported, with expansion of the disease to South Turkey 
(Alasaad, 2013). In the United States, infection is associated with travel and 
immigration; most of the cases are travellers that acquired the infection in Latin 
America, such as Costa Rica (Centres for Disease Control and Prevention, 
Epidemiology and Risk factors home page http://www.cdc.gov/parasites/ 
leishmaniasis/epi.html). 
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Fig. 1.4: Global distribution of visceral leishmaniasis. Sources: http://www.sanofi-
paediatrics.com/web/endemic/leishmaniasis/pathology. 
 
 
Fig. 1.5: Global distribution of cutaneous leishmaniasis. Adopted from Reithinger et 
al., (2007). 
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1.6 Leishmaniasis in dogs: 
 
Leishmaniasis in dogs or canine VL (CVL) is endemic in more than 70 countries 
in the world including South Europe, Africa, Asia, South and Central America 
(Baneth et al., 2008). The disease has been also reported in some non-endemic 
countries such as North America, United Kingdom, Netherland and Germany 
(Gothe et al., 1991; Petersen and Barr, 2009; Shaw et al., 2009). In these 
countries, infection is restricted to dogs that travelled to or have been imported 
from endemic countries in South Europe (Spain, France, Italy, and Turkey) 
(Gothe et al., 1991; Petersen and Barr, 2009). The risk of introducing 
leishmaniasis to Central Europe from Mediterranean countries depends on the 
climate and environmental conditions (Ready, 2010). The maximum northern 
latitude for the survival of sandflies may exceed the northern boundaries of 
Germany, creating better opportunities for survival of the sandfly vectors 
(Desjeux, 2001).  
 
Leishmaniasis in dogs causes a wide range of clinical signs including 
lymphadenopathy, weight loss, emaciation (extremely thin), hepatosplenomegaly, 
conjunctivitis, keratitis, onychogryphosis (thickening and increase in curvature of 
the nail) and lesions on skin, limbs and ears (Fig. 1.6). Infected dogs can also 
remain asymptomatic (Marzochi et al., 1985; Slappendell, 1988; Berrahal et al., 
1996).  
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Fig. 1.6: Signs of leishmaniasis in dogs: (a) purulent keratoconjunctivitis, (b) facial 
skin lesions, (c) epistaxis, (d) onychogryposis and (e) skin ulceration on the ear. 
Adopted from Baneth et al., (2008).  
 
1.7 Transmission and life cycle: 
 
Classically, leishmaniasis is a zoonotic disease, but human-to-human 
transmission has been reported in some regions (Molina et al., 2003). Different 
developmental cycles occur in humans, reservoirs and the sandfly vectors. An 
important feature is that, Leishmania transmission occurs in certain locations 
such as forests. However, epidemiology of the disease has changed and 
became more domestic and in settled areas due to deforestation and 
agricultural development (Walsh et al., 1993).  
 
The parasite has a complex life cycle, involving two developmental forms 
(digenetic parasite) in two different host species: a flagellated-extracellular 
promastigote stage within the sandfly and a non-flagellated-intracellular 
amastigote stage within the mammalian (human or animal) hosts. The different 
stages represent an adaptation to the internal environment within the hosts 
(Besteiro et al., 2007). 
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Sandfly: 
The sandfly (Fig. 1.7) is smaller than mosquitoes, with a body length of 2-3 mm. 
It belongs to the subfamily Phlebotominae, which includes two genera of 
medical importance: Phlebotomus in the ‘Old World’, and Lutzomyia in the ‘New 
World’. Out of the 500 known phlebotomine species, 31 are known as vectors 
for Leishmania and 43 as possible vectors. As in the case of mosquitoes, 
female sandflies require blood for egg production (haematophagous). Some 
phlebotomine species such as Phlebotomus papatasi and Phlebotomus 
sergenti are restricted vectors supporting the growth of certain species of 
Leishmania. Other species such as Lutzomyia longipalpis and Phlebotomus 
argentipes can support growth of several Leishmania species (see Banuls et 
al., 2007). In Sudan, Phlebotomus orientalis transmits the disease in the North 
and the former southern part of the country (Ashford et al., 1992). This species 
lives in areas with Acacia seyal/Balanites aegyptiaca vegetation and black 
cracking cotton soil (Fig. 1.8) (Elnaiem et al. 1998). In sandfly, Leishmania 
transforms to promastigotes, a motile extracellular flagellated form (Fig. 1.9) 
(see Banuls et al., 2007). 
 
 
 
 
 
 
 
 
Fig. 1.7: Female Phlebotomus sandfly. Source: National History Museum, UK. 
(http://www.nhm.ac.uk/).  
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                                   (a)                                       (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.8: Sandfly breading sites: (a) Acacia Seyal trees and (b) black cotton soil. 
Photos were taken by the author (E. Abass) around Doka village, Gadaref State, a 
known VL-endemic area in Eastern Sudan.  
 
 
 
 
 
 
 
Fig. 1.9: Morphological forms of Leishmania parasites: (a) the flagellated-
extracellular promastigote stage and (b) the non-flagellated-intracellular amastigote 
stage in a macrophage cell. Source: http://www.leishinfonet.com/Morphology.php. 
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Mammalian Host: 
An important feature of Leishmania is their infectious potential of host cells such 
as macrophages. Beside humans and dogs, Leishmania can infect also other 
species such as rodents and canids. These species are considered potential 
reservoirs (Lainson and Shaw, 1987). In the mammalian host, Leishmania 
transforms into a non-flagellated intracellular ovoid amastigote form (2.5–5 µm 
diameter) with a well defined large nucleus and a smaller kinetoplast. (Fig. 1.9).  
 
Life Cycle (Fig. 1.10): 
Infected female sandflies inject a small number of infectious metacyclic 
promastigotes into the skin. These forms are efficiently opsonized by serum 
components and taken up by macrophages, where they live in phagolysosomes 
and transform into non-flagellated amastigotes forms. Infected macrophages 
are taken up by sandflies during blood meals and lysed in the midgut of the 
sandflies. Here the parasites are released that transform into non-infectious 
promastigotes (procyclic promastigotes). These forms attach to the midgut wall 
and differentiate into non-dividing metacyclic promastigotes, which can be 
transmitted when the sandfly takes another blood meal (Sacks and Noben, 
2002; Besteiro et al., 2007).  
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Fig. 1.10: Life cycle of Leishmania parasites. Modified from Sacks and Noben 
(2002). 
 
1.8 Visceral leishmaniasis in Sudan and South Sudan: 
 
Today, Sudan and South Sudan belong to the six VL-endemic countries in East 
Africa, which constitute 90% of global VL cases (Alvar et al., 2012). In these 
countries, the disease affects poor communities in remote rural areas where 
many patients have no access to diagnosis and standard treatment services and 
often succumb undetected by the local health information system (Collin et al., 
2006). Since its discovery in 1904 in Sudan, VL is one of the biggest health 
problems in the country (see Zijlistra and Elhassan 2001).  
 
In North Sudan, Gedaref State is the main endemic focus with an incidence of 6.6 
- 8.4 cases per 1000 persons during 1996 to 1999. The main affected region is 
along two rivers "Atbarah and Rahad", in area with high rainfall (Ritmeijer and 
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Davidson, 2003; Elnaiem et al., 2003). Cases were also reported in small foci in 
West Sudan including Nuba Mountains and Darfur (Zijlstra and El-Hassan, 2001). 
Another endemic focus is the White Nile State in Central Sudan, where the 
disease reappeared after it had been under control for 25 years (Khalil et al., 
2008). In this area, cases were reported from 5 villages on the west bank of the 
White Nile with children (2-14 years) being most affected (Walyeldin et al., 2010). 
Due to the lack of health care in this area, patients had to travel for more than 100 
km to be treated in Omdurman Hospital in the capital.  
 
The armed conflicts over the last decades have caused serious environmental 
changes such as widespread destruction of houses and health infrastructures that 
resulted in increased exposure to sandfly and less accessibility to health care 
facilities. Non-immune or infected populations moved to VL-endemic or non-
endemic areas, causing major epidemics (Reithinger et al., 2007). Among several 
epidemics that occurred in the 20th century, the most severe was in the Upper 
Nile province (now in the new Republic of South Sudan) during 1984-1994 where 
one third of the population (100,000) were killed and 40,000 patients were treated 
(de Beer et al., 1991; Gorski et al., 2010). The problem has further been 
complicated by the massive exodus to South Sudan after independence. More 
than 18,000 cases were recorded since the outbreak started in September 2009, 
with children mostly affected. At least 720 people died, however the number is 
likely to be much higher (United Nation, News Centre, http://www.un.org/apps/ 
news/story.asp?NewsID=40232#.UZiUE6DCd48). 
1.9 Visceral leishmaniasis and HIV co-infection: 
Visceral leishmaniasis and human immunodeficiency virus (VL/HIV) co-infection 
is a global health problem in several countries (Desjeux, 1995). HIV-infected 
individuals are highly susceptible to VL, which then enhances HIV progression to 
AIDS (Alvar et al., 2008). These cases frequently develop atypical VL symptoms 
and thus complicate clinical diagnosis (Desjeux, 1995). Co-infections have been 
reported in 35 countries, most of the cases from countries of southern Europe. In 
these countries, 25-70% of adult VL patients also have HIV infection and 1.5-9% 
of AIDS cases have newly acquired or reactivated VL. Those patients have a 
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much shorter survival period than other AIDS patients (Desjeux, 1995; Alvar et 
al., 2008).  
VL/HIV co-infection has been also reported in East African countries such as 
Ethiopia, Kenya, Malawi, and Sudan. In Ethiopia, HIV co-infection was reported in 
92 (38%) patients with VL. These cases showed much more treatment failure and 
death (Hurissa et al., 2010). In Sudan, the reported prevalence was 5% (3/60) in 
Khartoum between 1998 and 1999, 9.4% (5/53) in 2002, 8.1% (3/37) and 3.6% 
(3/84) in 2002 and 2003, respectively, in Gedaref State (Alvar et al., 2008). In a 
cross-sectional study included 204 VL patients from Sudan during 2003 – 2007, 
HIV co-infections were confirmed in 4.9% of the cases, all of them were male 
aged between 25 and 46 years (Abass and Elhussein, 2009).  
1.10 Laboratory diagnosis:  
 
1.10.1 Cutaneous and mucosal leishmaniasis: 
 
In areas with high endemicity, appearance of characteristic lesions is sufficient 
to establish clinical diagnosis. However, laboratory procedures are required to 
differentiate leishmaniasis from other dermal conditions such as tropical ulcers, 
impetigo, infected insect bites, leprosy, lupus vulgaris, tertiary syphilis, yaws, 
blastomycosis, skin cancer (see Singh, 2006). Diagnostic procedures are based 
on:  
 
(i) Parasitological methods by direct detection of Leishmania in lesional 
specimens of Giemsa-stained smears or culture. The latter is useful for 
the identification of the species and selection of therapy. These methods 
are time consuming, laborious and have low sensitivities (Weigle et al., 
1987). 
 
(ii) Molecular biology using PCR techniques are very sensitive and useful to 
determine the species of the parasite but require invasive procedures for 
specimen collections (de Oliveira et al., 2003; Bensoussan et al., 2006).  
 
(iii) Serologically methods based on antibody detection are easy and fast 
but lack enough sensitivity due to the low number of circulating 
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antibodies and probably antigenic diversity of the parasites causing the 
disease (Reithinger and Dujardin, 2007; Szargiki et al., 2009).  
 
(iv) Leishmanin skin test (LST) is a useful marker for cutaneous and 
mucocutaneous leishmaniasis (Weigle et al., 1991). It is used to 
measure cell-mediated immune responses, which is an important 
feature of cutaneous leishmaniasis. The antigen is a suspension of killed 
promastigotes of L. major (Reithinger and Dujardin, 2007).  
 
(v) Isoenzyme characterization and monoclonal antibodies are used for 
species typing. 
1.10.2 Visceral leishmaniasis:  
 
Diagnosis of VL is complex because the common clinical symptoms are shared 
with other diseases that are endemic in the same regions such as malaria, 
typhoid and tuberculosis. These diseases may occur together with VL in the same 
patients (de Beer et al., 1991; van den Bogaart et al., 2012). VL should be 
suspected if a patient has persistent fever (>2 weeks) and splenomegaly and is 
living in or visited a VL-endemic area (WHO, 1996). Definitive diagnosis of VL is 
typically done by laboratory tests. These tests are based on:  
 
(i) Detection of Leishmania donovani (L.D) in aspirates of lymph node, bone 
marrow or spleen by light microscope. These techniques have varying 
diagnostic sensitivities, depending on the type of specimen. Spleen 
aspiration has the highest sensitivity (93.1% - 98.7%) (Siddig et al., 1988; 
Zijlstra et al., 1992), but can be associated with serious complications 
such as bleeding or even rupture of the spleen (Chulay and Bryceson, 
1983). Bone marrow aspiration has lower sensitivity (52% - 85%) but less 
invasive than spleen aspiration (Zijlstra et al., 1992; Bryceson, 1996). 
Lymph node aspiration is safe but has the lowest sensitivity (52% - 58%) 
(Siddig et al., 1988; Zijlstra et al., 1992). In a hospital based study in 
Sudan, detection of Leishmania in lymph nodes showed a sensitivity of 
only 20%, lower than been described before (Walyeldin et al., 2010). In 
cases of co-infection with HIV, the parasites can be also detected in 
peripheral blood smears (Delgado et al., 1998).  
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(ii) Detection of the parasites in culture. Samples can be cultured in NNN-
medium or golden hamsters. However, the latter is not applied in clinical 
practice. For cases of VL/HIV co-infection, buffy coat or blood cultures can 
be used with varying sensitivity, 67% - 92% (Lopez-Velez et al., 1995; 
Salam et al., 2012). 
 
(iii) Detection of Leishmania DNA in clinical samples using polymerase chain 
reaction (PCR). These assays include several formats. In conventional 
assays, specific PCR amplicons are resolved by electrophoresis after 
cleavage with restriction enzymes such as PCR-restriction fragment 
length polymorphism analysis (PCR-RFLP). In other assays, PCR 
products are analyzed during amplification cycles (real-time PCR) after 
staining with SYBR-green I dye or hybridization with fluorogenic probes 
(TaqMan or fluorescence resonance energy transfer (FRET) (see 
Reithinger, et al., 2007). These techniques are very sensitive for diagnosis 
of VL, even in patients with negative parasitological- and Leishmanin skin 
tests (Marques et al., 2006; Srivastava et al., 2011a). However, PCR is 
not a good marker for clinical VL as it may remain positive after treatment 
(Deborggraeve et al. 2008). In addition, the need for standard laboratory 
equipments and the risk of contamination limit their routine use.  
 
(iv) Immunodiagnostic methods, which include serological tests for antibody 
detection and assays to measure Leishmania-specific cell-mediated 
immunity. Specific antibodies can be detected through different methods 
such as Enzyme-linked Immunosorbent Assay (ELISA), Immuno-
fluorescent Antibody Test (IFAT), Direct Agglutination Test (DAT) and 
Immunochromatographic rapid tests.  
Direct Agglutination Test (DAT): 
DAT is an agglutination assay that uses intact stained promastigotes either in 
suspension or in a freeze-dried form (Harith et al., 1986; Meredith et al., 1995). 
The test is simple to perform and requires no sophisticated machines, thus being 
an ideal test for field use. It has proven to be a useful tool for diagnosis of VL in 
several countries including Sudan (Mengistu et al., 1990; Shiddo et al., 1995; 
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Boelaert et al., 1999a; Abass et al., 2007; Hamzavi et al., 2012). The stability of 
DAT for field application was improved by using freeze-dried and glycerol 
preserved antigens which do not require storage at 4°C (Meredith et al., 1995, 
Harith et al., 2003). However, the need for overnight incubation gives limitation for 
the field use.   
Enzyme Linked Immunosorbent Assay (ELISA): 
ELISA is easy to standardize and practical for routine application. The 
performance of the test depends on type of antigen and can be improved by 
using recombinant proteins. Conventional water soluble antigens are highly 
sensitive but less specific (Bray, 1985). Several recombinant antigens have been 
characterized and used in ELISA for serodiagnosis of VL (Burns et al., 1993; 
Sivakumar et al., 2006; Carvalho et al., 2002; Goto et al., 2006; Pattabhi et al., 
2010). Among these antigens, the rK39, which is a kinesin protein of L. infantum 
(synonymus L. chagasi), has shown the best performance in several endemic 
regions (see Chappuis et al., 2007; Maia et al., 2012; Machado de Assis et al., 
2012).    
Immunochromatographic rapid tests (RTs):  
RTs are strip-based assays that can be carried out directly on-site without large 
efforts: only a blood sample of the patient is required. This format has the 
advantages of being ready for use and rapid. Commercially available RTs for VL 
are either based on rK39 of L. infantum (Burns et al., 1993) or rKE16 of L. 
donovani (Sivakumar et al., 2006). These tests are quite effective in diagnosing 
VL in several countries (Singh et al., 1995; Badaró et al., 1996; Ozensoy et al., 
1998; Medrano et al., 1998; Houghton et al., 1998; Maalej et al., 2003).  But, their 
use for East Africa is not satisfactory (Zijlstra et al., 2001; Veeken et al., 2003; 
Ritmeijer et al., 2006). Recently, it has been shown that RTs based on either rK39 
or rKE16 have considerable variation in the major endemic regions for VL (Indian 
subcontinent, East Africa, Brazil). These tests have been performed with high 
sensitivity in the Indian continent (92.8%-100%) but not in Brazil (61.5%-91%) 
and East Africa (36.8%-87.2%) (Cunningham et al., 2012). 
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Indirect Fluorescent Antibody Test (IFAT): 
IFAT is routinely used for serodiagnosis of leishmaniasis in dogs. It has similar 
sensitivity as DAT (88.3% and 88.5%) but lower specificity, 83% for IFAT and 
95.4% for DAT (Machado de Assis et al., 2012). IFAT is difficult to standardize 
and to interpret and is not suitable for screening of large numbers of samples.  
Western Blot (WB) analysis: 
Application of WB for detection of Leishmania-specific antibodies is limited only 
for research purposes and is not adopted for routine diagnosis.  
Leishmanin Skin Test (LST): 
LST is typically used as a marker for successful VL treatment (Weigle et al., 
1991). During active VL, patients show no cell mediated immune response and 
thus test negative, but convert to positive after successful treatment (Zijlstra and 
El-Hassan, 2001).  
1.11 Immunity against Leishmania: 
 
Immunity against Leishmania parasites is mediated by both innate (neutrophils, 
macrophages, and dendritic cells) and adaptive immune mechanisms 
(Kedzierski, 2010). The parasite is able to infect a variety of host cells and 
manipulate signalling pathways, which are involved in killing of pathogens or in 
stimulating immune responses (Shio et al., 2012). Neutrophils are the earliest 
cells recruited to the site of infection, also representing the first infected cells. 
They serve as intermediate host cells, helping the parasite to enter 
macrophages silently (van Zandbergen et al., 2004). Leishmania enters 
macrophages through a classical receptor-mediated process. This includes 
several parasite and macrophage surface molecules such as the complement 
receptors (CR)1, CR3 (Mac-1), fibronectin receptor and the mannose-fucose 
receptor (MR) on the surface of macrophages. These receptors recognise 
special structures on the surface of promastigotes include surface 
lipophosphoglycan (LPG), major surface protease (GP63), and 
proteophophoglycans (PPG) of L. major promastigotes (Liu and Uzonna, 2012).  
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Macrophages and dendritic cells, the two major antigen presenting cells 
(APCs), play an essential role in susceptibility to or resistance against 
Leishmania infection (Liu and Uzonna, 2012; McCall et al., 2013). They initiate 
adequate defence mechanisms by presenting antigens of the parasite via the 
major histocompatibility complex class II (MHC-II) molecules to T cells (Lang et 
al., 1994). Subsequently, T cells produce cytokines, influencing various immune 
responses by which Leishmania can evade or interfere with immune 
mechanisms (see Banuls et al., 2007). 
 
In humans, different patterns of immune responses exist which are associated 
with the various clinical forms of the disease and parasite species. Active 
disease is characterized by strong Th2 responses and absent or low Th1 
responses (Reed and Scott, 1993; Herwaldt, 1999). In VL, several reports have 
shown impaired lymphocyte function with suppression of type 1 cytokines such 
as IL-2, IFN-γ and IL-12, which is associated with increased type 2 cytokines 
including IL-4 and IL-10 (see Dey et al., 2008). Other authors have shown 
mixed Th1/Th2 immune responses with production of IFN-γ and IL-10, which 
significantly decrease after cure. This suggests that both cytokines are involved 
in the regulation of the immune responses against VL (Ghalib et al., 1993; 
Kenney et al., 1998; Ansari et al., 2006). Individuals with subclinical or 
asymptomatic infections demonstrate peripheral blood mononuclear cell 
(PBMC) proliferation with production of IL-2, IFN-γ and IL-12 (Kemp et al., 
1993). 
 
IFN-γ exerts different immune-protective mechanisms in Leishmania infection. It 
mediates macrophage activation and production of nitric oxide (NO), which 
plays an important role in intracellular killing of Leishmania (Liu and Uzonna, 
2012). To prevent killing by macrophages, Leishmania manipulates 
macrophage activity by impairing the ability to produce IL-12 (an important 
cytokine for CD4+ Th1 development and IFN-γ production) via synthesis of 
immuno-regulatory cytokines such as IL-10 and TGF-β (Liu and Uzonna, 2012). 
Increased levels of IL-10 and TGF-β are associated with disease progression 
through counteracting IFN-γ effects and deactivation of macrophage function 
(Barral-Netto et al., 1992; Cillari et al., 1995). Both IL-4 and IL-10 have shown 
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to inhibit intracellular killing of L. infantum and L. major by human macrophages 
through inhibiting NO production (Vouldoukis et al., 1997). 
 
VL patients demonstrate increased humoral antibody responses, including IgG, 
IgM, IgE and IgG isotypes (Chatterjee et al., 1998; Anam et al., 1999; 
Ravindran et al., 2004). These antibodies have little effect in clearance of the 
parasite, but their specific function is still unclear. Miles and colleagues (2005) 
have shown that IgG not only fails to provide protection against Leishmania but 
also causes disease progression via inducing IL-10 production in macrophages. 
IgG-coated Leishmania can bind to macrophage Fc receptors (FcγR) and 
facilitate phagocytosis. It also activates downstream pathways and thus prevent 
killing and promote intracellular survival and growth of the parasites (Miles et 
al., 2005). 
 
1.12 Variation and genetic polymorphism in Leishmania parasites: 
 
Leishmania is a group of parasites with a wide ecological, epidemiological and 
clinical diversity (Shaw, 1997). These parasites have adapted to survive in 
diverse environments and are able to infect different mammalian hosts. Climatic 
and environmental factors impose strong selective pressure and may affect 
population genetics. Data indicate that the geographical distribution, the range 
of vectors and/or mammalian hosts have an influence on the genetic 
heterogeneity of Leishmania (see Banuls et al., 2007).  
 
Genetic variations and heterogeneity of Leishmania parasites have been shown 
in several studies where L. braziliensis complex and L. mexicana complex 
revealed more diversity than L. guyanensis and L. donovani complexes (see 
Banuls et al., 2007). Species of L. donovani complex from different countries 
exhibit extensive genetic variation, which has been confirmed using different 
parasite-specific sequences. These parasites are grouped in six main 
genetically distinct populations based on multilocus enzyme electrophoresis 
(MLEE), where different allelic diversities were detected with a high degree in 
Mediterranean region, intermediate in Africa and lowest in India (Kuhls et al., 
2007).  
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Analysis of L. donovani strains from East Africa and India show considerable 
heterogeneity with the existence of more than one genetic variant or mixed 
population in the same region (Kuhls et al., 2007; Srivastava et al., 2011b). East 
African strains are grouped into two genetically and geographically populations, 
strains from South Ethiopia and Kenya in one population and strains from North 
Ethiopia and Sudan in a second population. These parasites are derived from 
two different sandfly vectors, Phlebotomus orientalis in North Ethiopia and 
Sudan, Phlebotomus martini in South Ethiopia and Kenya. The existence of 
distinct clonal populations with putative hybrid genotypes at the same region 
indicates a mixed-mating system (Gelanew et al., 2010). In particular, strains of 
L. donovani from East Sudan are markedly diverse (heterogeneic) (Hamad et 
al., 2010).  
 
Antigens of Leishmania reveal also marked heterogeneity among different 
species and within strains from the same regions. Kinesin proteins of L. 
donovani exhibit polymorphisms in the immunodominant repeats with multiple 
amino acid substitutions among East African and Asian strains. Coding 
sequences of rK39 homologues of East African and Asian L. donovani strains 
significantly differ from the rK39 of L. chagasi, with much more heterologeneity 
among strains from East Africa (Bhattacharyya et al., 2013). Other Leishmania 
antigens demonstrate also genetic polymorphism. The cysteine proteinase B 
(cpb) and gp63 exhibit intragenic and intergenic regions specific polymorphism 
among subspecies of L. donovani complex (Tintaya et al., 2004). HASPB 
(Hydrophilic acylated surface protein B) contains polymorphisms in the 
immunodominant repeat regions of L. donovani and L. infantum (Zackay et al., 
2013; Bhattacharyya et al., 2013).  
 
1.13 Control strategies of visceral leishmaniasis:   
 
Efficient control strategies against human VL are primarily based on the control of 
reservoir hosts and the vector as well as diagnosis and treatment of patients. 
Detection and treatment of infected dogs is limited by the fact that dogs may 
relapse or re-infected after successful treatment (see Chappuis et al., 2007). 
Studies have shown that culling of infected dogs reduces incidence of the disease 
in both dogs and humans, but this strategy is not accepted ethically (see Romero 
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and Boelaert, 2010). Vector control through insecticide spraying is a useful 
strategy in India because the sandfly lives in and around homes. In other endemic 
areas such as Sudan, infections occur outside villages and therefore spraying of 
houses and insecticide-treated bednets (ITNs) are not useful. Early detection is 
essential for treatment of patients and infection control. Without treatment, VL 
patients are sources for spread of the parasite. Thus, early case detection and 
treatment remains an efficient strategy for VL control (see Chappuis et al., 2007).  
 
1.14 Visceral leishmaniasis treatment:  
 
Treatment of VL is based on anti-leishmanial drugs and management of other 
complications such as secondary bacterial or parasitic infections and anaemia. 
Pentavalent antimonials, sodium stibogluconate (Pentostam®) and meglumine 
(Glucantim®), are used as the first-line treatment in most VL endemic areas. 
These drugs are very toxic and associated with severe side effects such as 
cardiac arrhythmia and acute pancreatitis. Antimonials should be given with 
caution for children and old patients (<2 and >45 years) and to patients with 
advanced disease or malnutrition. Resistance to antimonials are common in 
several countries, which may reach >60% (see Chappuis et al., 2007).  
 
Amphotericin B is an alternative drug and currently used in some countries such 
as India. Its side effects include infusion-related fever, chills, rigor, hypokalemia 
(low potassium levels in the blood), nephrotoxicity (toxic to kidney cells) and first-
dose anaphylaxis. Liposomal amphotericin B is the best available drug and is 
currently used in Europe and the United States. Its use in developing countries is 
limited by the high cost (see Chappuis et al., 2007). Miltefosine is the first and still 
the only oral drug available for VL and CL. It has a high cure rate and less toxicity 
but has mild gastrointestinal side effects (Dorlo et al., 2012). Paromomycin, which 
is an aminoglycoside antibiotic, has high anti-leishmanial efficacy and acts also 
against bacterial infections. Combination therapy was suggested to increase 
efficacy, lower drug resistance and reduce duration of treatment. Combination of 
sodium stibogluconate and paromomycin has shown to be safe and effective. 
Other trial includes the use of liposomal amphotericin B and miltefosine (see 
Chappuis et al., 2007). 
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1.15 Rational and objectives: 
 
1.15.1 Rational: 
Diagnosis of VL is a major health problem for poor communities with limited 
resources. To date, there are no reliable diagnostic tests for VL in East Africa. 
Available tests have many limitations, none of them is sufficient to identify all 
positive and negative cases. A negative result doesn’t rule out infection and 
false positives are common. Patients co-infected with other diseases such as 
HIV and malaria may show atypical clinical pictures with marginal antibody titres 
and are inaccurately diagnosed. In addition, VL shares clinical features with 
other diseases such as typhoid, malaria and tuberculosis. These diseases often 
overlap the same VL-endemic areas and thus making clinical diagnosis difficult.  
 
In Sudan, detection of Leishmania parasites in lymph nodes and direct 
agglutination test (DAT) are currently used for the diagnosis. These tests, 
however, are either not sensitive and invasive or need overnight incubation, 
giving limitations for the field use. The available rapid tests which are usually 
based on a single antigen of parasite from Brazil (L. chagasi) are inaccurate in 
Sudan. In addition, these tests can neither differentiate between active and past 
infections nor between symptomatic and asymptomatic infections.  
Due to their role in transmission cycle of VL, infected dogs should be controlled.  
If not detected and treated, infected dogs are continuous sources of the 
parasites for the sandfly vectors. As for humans, currently used tests for canine 
VL have low sensitivity. Cross-reactivity with other diseases and low sensitivity 
in detecting asymptomatic dogs are further limitations.   
For all these reasons, research on Leishmania is necessary to develop better 
diagnostic procedures for VL especially for those in rural areas of East Africa. In 
particular, there is a need for simple-rapid, cheap and accurate tests with high 
sensitivity and specificity. These tests should be able to discriminate between 
VL and potential co-infections and to detect asymptomatic infections in humans 
and dogs.  
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1.15.2 Aim and Objectives: 
The aim of this study was to integrate current knowledge about genetic 
variability of Leishmania and heterogeneity of antigens in order to develop a 
better diagnostic test for VL. Specific objective are: 
 
i- To improve diagnosis of VL in Sudan by using antigens from 
autochthonous L. donovani strain.  
 
ii- To evaluate serodiagnostic tests in major endemic regions for human and 
canine VL in order to identify appropriate diagnostic tests for different 
regions.  
 
iii- To explore whether heterogeneity of Leishmania antigens has influence 
on reactivity and thus performance of the serological tests. 
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2. MATERIALS AND METHODS:  
 
2.1 MATERIALS: 
 
2.1.1 Chemicals and reagents: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Company  
Acrylamide mix Carl Roth 
Agar  Merck  
Agarose Biozym 
Ammonium persulfate Sigma  
Ampicillin Sigma 
BM blue POD substrate  Roche 
BSA Sigma  
Coomassie brilliant blue Merck 
DMSO 
 
 
Fluka 
DNA ladder standard  
 
 
Fermentas 
DNA loading dye (6X ) 
 
 
Fermentas 
Donkey anti-Human IgG JaksonImmunoResearch Labs 
EDTA Sigma  
Ethanol Sigma 
Ethidium bromide Fluka 
FCS Sigma 
Gelatine  Fluke 
Glycerine  Carl Roth  
Glycin Carl Roth  
H2O2 R&D system 
Imidazol Carl Roth 
IPTG Carl Roth 
Kanamycin GERBU Biotechnik 
LB broth Invitrogen 
NaCl Sigma 
NaHCO3 Sigma 
NaPO4 JT Baker 
PBS Dulbecco Biochrom 
PMSF Sigma 
Potassium acetate Carl Roth 
Rabbit anti-Dog IgG JaksonImmunoResearch Labs 
Sodium dodecyl sulfate (SDS) Sigma 
ß-mercaptoethanol Sigma 
Sucrose Sigma 
TEMED Sigma  
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2.1.2 Enzymes: 
 
Enzyme  Company  
Antarctic phosphatase New England Biolabs 
BamHI Fermentas 
Benzonase nuclease Novagen 
DNA ligase New England Biolabs 
DNase1 Invitrogen 
EcoRV Fermentas 
Lysozyme Carl Roth 
Phusion DNA polymerase Finnzymes 
Phusion Hot start II DNA 
Polymerase 
Thermofisher   
RNase Biozyme  
SalI Fermentas  
 
2.1.3 Commercial kits: 
 
Kit  Company  
Crystal KA rKE16 Span Diagnostic, India 
Gentra Puregene cell kit  Qiagen 
IT LEISH rK39 Bio Rad 
ITMA-DAT/VL Institute of Tropical Medicine, 
Antwerp 
Ni-NTA column Qiagen 
Nucleospin Gel and PCR clean-up Macherey- Nagel 
NucleoSpin Plasmid Midi kit Macherey- Nagel 
NucleoSpin Plasmid Mini kit Macherey- Nagel 
 
 
2.1.4 Culture media: 
RPMI-1640 (Sigma): Supplemented with L-glutamine (0.3 g/L), NaHCO3 (2.0 g/L) 
and 10% (v/v) fetal calf serum. 
 
Luria Bertani (LB) broth and agar media:  
Standard ingredients for 1 Liter:  
• Tryptone                                10 g 
• Yeast Extract                           5 g 
• NaCl                                      10 g 
Name Company  
Tertamethylbenzidine R&D system 
Tris-Base Acros 
Tris-HCl Carl Roth  
Tween 20 OmniPur 
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20 g LB broth base (Invitrogen) was dissolved in 1 litre of distilled water.  For 
LB agar, 15 g agar (Merck) was added. The mixture was heated to boil and 
dissolve the agar which was then sterilized by autoclaving for 15 minutes at 
121°C (15 psi).  
 
Additives:  
Antibiotics and additives were prepared as stock solutions, sterilized using 0.22 
µm membrane filters (Millipore) and then added to the media after autoclaving.  
 
Table 2.1: Culture medium additives: 
 
 
Substance 
 
Solvent 
 
Stock 
concentration 
 
Final 
concentration 
 
 
        Ampicillin (Sigma) 
 
H2O 
 
100 mg/ml 
 
100 µg/ml 
 
Kanamycin (GERBU 
         Biotechnik) 
 
H2O 10 mg/ml 25 µg/ml 
         IPTG (Carl Roth) H2O 1 M 1 mM 
 
 
 
2.1.5 Solutions and buffers: 
 
β-ME stock solution (10 mM): 
 
 
 
 
 
 
 
2-ME 700 µl 
PBS 1000 ml 
Sterilize by filtration. 
 
Freezing media: 
For Leishmania: 
RPMI 1640 contains 10% FCS
                      
8 ml 
FCS
 
1.2 ml 
DMSO
 
1 ml 
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For bacteria: 
Bacterial culture  900 µl 
DMSO  100 µl  
 
DNA isolation buffers: 
Cell Lysis Solution: 10 mM Tris-HCl pH 8.0, 25 mM EDTA, 0.5% (v/v) SDS. 
1M Tris-HCl 1 ml 
0.5M EDTA          5.0 ml 
20% SDS (w/v)          2.5 ml 
H2O          91.5 ml 
 
Protein Precipitation Solution: 5 M Ammonium Acetate, NH4OAc, Mr = 77.09. 
 NH4OAc                                                  19.27 g 
 H2O                                     to 50 ml 
 
DNA electrophoresis buffers: 
5X TBE Buffer: 
Tris-Base                                                        540 g 
Boric acid                                                       2.75 g 
0.5 M EDTA (pH 8.0)                                     200 ml 
Water                                                             up to 10 L.  
 
50X TAE Buffer: 
Tris-Base                                                       2.42 kg 
Acetic Acid                                                    571 ml 
0.5 M EDTA (pH 8.0)                                    1 L 
Water                                                            up to 10 L. 
 
6X DNA loading Buffer:        
Sterile H2O                                                    1 ml 
Glycerol                                                         1 ml 
Bromophenol blue                                         ~ 0.05 mg  
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Buffers for chemically competent E. coli: 
 
 
 
RF1 buffer: 1 M potassium acetate, pH 7.5 
1 M potassium acetate 15 ml 
Rubidium chloride (RbCl) 6 g 
Manganese chloride (MnCl2 4 H2O) 4.95 g 
Glycin 75 g 
Water Complete to 500 ml 
Adjust pH to 5.8, sterilize by autoclaving.  
 
RF2 buffer: 
MOPS (3-(N-morpholino)propanesulfonic acid) 
(0.5 M, pH 6.8) 
10 ml 
RbCl 0.6 g 
CaCl2 X2 H2O 5.5 g 
Glycin 75 g 
Water Complete to 500 ml 
Adjust pH to 5.8, sterilize by autoclaving.  
 
Plasmid cracking solution: 
2 N NaOH 100 µl 
10% SDS (w/v) 50 µl 
Sucrose 0.2 g 
H2O complete to 1 ml (~ 850 µl) 
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Protein purification buffer: 
 
Table 2.2: Imidazol buffers:  
Final concentration  
Stock 10 mM 20 mM 60 mM 400 mM 
10X PBS pH 7.4 10 ml 10 ml 10 ml 10 ml 
    β-ME 4 µl 4 µl 4 µl 4 µl 
    1 M imidazol 1 ml 2 ml 6 ml 40 ml 
    0.1 M PMSF 1 ml 1 ml 1 ml 1 ml 
H2O 84 ml 83 ml 79 ml 49 ml 
 
SDS-polyacrymide gel:  
Resolving gel 12%: for 5 ml 
H2O 1.6 ml 
30% acrymide mix 2.0 ml 
1.5 M Tris-HCl (pH 8.8) 1.3 ml 
10% SDS 0.05 ml 
10% ammonium persulfate 0.05 ml 
TEMED 0.002 ml 
 
Stacking gel 5%: for 1 ml 
H2O 0.68 ml 
30% acrymide mix 0.17 ml 
1.5 M Tris-HCl (pH 8.8) 0.13 ml 
10% SDS (w/v) 0.01 ml 
10% ammonium persulfate 0.01 ml 
TEMED 0.001 ml 
 
Protein electrophoresis and WB buffers: 
10X electrophoresis running buffer: 
2 M glycin  
0.25 M Tris-Base 
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1X electrophoresis buffer: 
10X running buffer        100 ml 
10% SDS (w/v)        10 ml 
H2O        To 1000 ml 
 
4X sample buffer: 
150 mM Tris-HCl (pH 6.8) 
1.2% SDS 
3.3% glycerine (v/v) 
1.8% bromphenol blue (w/v) 
 
10X WB transfer buffer: 
Glycin 2 M 
Tris-HCl 250 mM pH 8.8 
 
1X WB transfer buffer: 
10X transfer buffer 30 ml 
Methanol  60 ml 
H2O 210 ml 
 
WB wash buffer 
100 mM NaCl 
10 mM Tris-HCl pH 7.5 
0.05 Tween 20 (v/v) 
 
WB blocking buffer 
100 mM NaCl 
10 mM Tris-HCl pH 7.5 
0.05 Tween 20 (v/v) 
5% BSA (w/v) 
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ELISA buffers: 
Coating buffer: 
0.1 M NaHCO3   (MW = 84.01g/mol)  pH 9.6                     
 
Blocking and sample buffer:  
BSA 3 g 
PBS 100 ml 
Tween 20 0.05 ml 
 
Wash buffer: 
0.05% Tween 20 in PBS (v/v) 
 
2.1.6 Leishmania strains:  
 
L. donovani LO8 was used for amplification and expression of the 
immunodominant kinesin protein gene. For sequence comparison, similar 
published DNA and amino acid sequences of other L. donovani strains (Table 
2.3) were obtained from public domain of the National Centre for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov/).   
 
Table 2.3: Leishmania donovani strains and isolates: 
 
   Strain Geographical origin Reference code/isolate 
   L. donovani LO8      Sudan     Sudanese isolate 
   L. donovani 1S      Sudan     MHOM/SD/62/1S-CL2D 
   L. donovani KE16      India     MHOM/IN/1998/KE16 
   L. donovani DD8      India     MHOM/IN/DD8/1968 
   L. donovani Morena      India     Indian isolate 
   L. donovani DD8      Bangladesh     Bangladeshi isolate 
   L. chagasi BA-2      Brazil     MHOM/BR/82/BA-2 
   L. infantum  LON49      Iran     MCAN/IR/96/LON-49 
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2.1.7 Bacterial strains: 
 
Different bacterial strains (Tables 2.4) were used for expression of the 
recombinant protein. Expression in M15 E. coli was found to be better and thus 
this strain was used for up-scaling protein production. 
 
Table 2.4: Bacterial strains: 
 
Name Characteristics Source 
 
  E. coli Top10  Host for cloning and plasmid   
 propagation. 
Invitrogen 
 
 
  
  E. coli M151 
  
 Contains the repressor pREP4 which   
 permits high- level protein expression  
 with pQE-vectors. 
 
   E. coli XL1 blue2 
 
  E. coli TG12 
 
 Harbors the lacIq mutation (lacIqZ∆M15 
 gene) to increase transcription. 
 
 
 
 
 
 
 
 
 
 
 
 
Qiagen 
 
E. coli strains were kindly offered by Prof. Mohamed Marahiel, Biochemistry- Marburg 
University1 or Dr. Maria Llamazares-Prada, Department of Dermatology and Allergy, 
Marburg University2. 
 
2.1.8 PCR primers: 
Oligonucleotide primers for amplification of the immunodominant kinesin 
protein gene of L. donovani (KLO8) were designed according to published L. 
chagasi gene for kinesin-related protein (GenBank: L07879.1). To express the 
recombinant protein, KLO8 was subcloned into the His-tag vector pQE41 
(Qiagen GmbH, Germany) using primers designed to contain an extra bases 
sequence at the 5´ end of the primers overhang specific sequence of the 
vector. Primers included also the restriction sites BamHI and SalI (underlined).  
 
Primers for cloning KLO8:  
Forward: 5'- GAGCTCGCAACCGAGTGGGAGG–3´  
Reverse: 5'- GCTCCGCAGCGCGCTCC–3'  
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Primers for subcloning: 
Forward: 5'-GTGGAATTCTGCAGATGGATCCATGGAGCTCGCAACC–3´  
Reverse: 5'-GCCGCCACTGTGCTGGATGTCGACGCTCC–3´ 
 
Sequencing primers for pcDNA 3.1(+) vector: 
Forward (T7 promoter): 5’TAATACGACTCACTATAGGG-3’ 
Reverse (BGH):             5’-TAGAAGGCACAGTCGAGG-3’ 
 
Sequencing primers for pQE41 vector: 
EApQE41 forward:  5’- TTCACACAGAATTCATTAAAG-‘3 
EApQE41 reverse:  5’- TCTATCAACAGGAGTCCAAGC-‘3 
 
2.1.9 Plasmids: 
 
Table 2.5: Plasmid vectors: 
 
Plasmid Description Source 
 
pcDNA3.1(+) 
 
 Used for cloning and plasmid propagation,  
 carries ampicillin resistant gene (Amp˄R). 
 
Invitrogen 
 
 
  pQE411 
 
 
 A His-tag protein expression vector,  
 carries Amp˄R gene. 
 
 
Qiagen 
 
pcDNA/KLO8 
  
 A new generated plasmid carrying KLO8  
 which was cloned into pcDNA3.1(+)   
 EcoRV site. 
 
 
pQE41/KLO8 
 
 A new generated plasmid carrying KLO8,   
 was inserted into pQE41 BamH1-Sal1  
 site and down stream of a 6x His-tag.    
 Used for expression of the recombinant   
 protein KLO8 
 
 
 
    Generated 
 in this study 
 
1
 Kindly offered by Dr. Cassian Sitaru, Department of Dermatology, University medical 
centre- Freiburg. 
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2.1.10 Analysis and bioinformatics online tools: 
 
Software  Website   
ApE Plasmid Editor http://biology.utah.edu/jorgensen/wayned/a
pe/ 
BLAST analysis tool http://blast.ncbi.nlm.gov/blast 
ClustalW2-Sequence Alignment http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
ExPASy Proteomics server  Htt://web.expasy.org/translate/ 
GraphPadPrism4 http://www.graphpad.com 
Sequin  http://www.ncbi.nlm.nih.gov/Sequin/ 
Tandem Repeat Finder http://tandem.bu.edu/trf/trf.html  
 
2.1.11 Serum samples: 
 
 
 
 
 
 
Human sera: 
 
 
 
A total of 324 human serum samples of patients and controls were obtained 
from established serum collection banks (Table 2.6). Sera were collected in 3 
endemic regions of VL in Doka-East Sudan, Bihar-North India and South 
France. Samples included 158 sera of VL, 11 sera of proven VL/HIV co-
infection cases. 24 sera were from symptomatic patients with unconfirmed VL 
diagnosis (VL suspects, VLS) from India and France. Twenty-five sera were 
from asymptomatic cases (ASC) from the same VL-endemic area in France. 
Control samples included sixty sera from healthy individuals with no previous 
history of leishmaniasis collected in a non-endemic areas (non-endemic 
control, NEC) or from the same VL-endemic area (endemic controls, EC). The 
control samples also included sera from patients with malaria, TB, leukaemia 
and toxoplasmosis. 
 
Selection criteria and characteristics of sera: 
 
 
Diagnosis of VL was established by detection of Leishmania amastigotes in 
Giemsa-stained smears of lymph nodes (Sudan), spleens (India) or bone 
marrows (France) aspirations and/or by culture in Novy, Nicolle and McNeal 
(NNN) medium (reference method). Patients with positive smear or culture 
results were categorised confirmed VL. Diagnosis was performed in the same 
endemic area by experienced personnels. Smears were repeated for 
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symptomatic patients with negative results. Patients with repeated negative 
results were defined as unconfirmed VL suspects (VLS). All sera of VLS from 
France have shown positive reactivity in ELISA and Western blot (WB) 
analysis using L. infantum soluble antigen (SLA). This strain was characterised 
by zymodeme analysis and found to be representative for the local strains in 
France. Confirmed VL sera from France were classified based on their HIV 
status into VL with HIV-negative or HIV-positive (VL/HIV). Sera of 
asymptomatic cases were selected based on their positive reactivity to 14 and 
16 kDa antigens in WB using the SLA, which are common in all Leishmania 
species (Mary et al., 1992).  
 
Table 2.6: Origin, source and number of human serum samples: 
 
Origin 
(no. of sera) 
Supplier Clinical condition 
(no. of sera) 
VL (n=106) 
Healthy (n=50) 
 
1 Doka, 
Eastern Sudan 
(n=183) 
 
Dr. Durria Mansour, Biomedical 
Research Laboratory of Ahfad, 
Omdurman, Sudan 
Malaria 
TB 
Leukemia 
(n=11) 
(n=10) 
(n=6) 
 
VL 
 
(n=26) 
VLS (n=11) 
Healthy (n=10) 
Toxoplasmosis (n=9) 
 
Bihar, North 
India (n=66) 
 
Prof. Peter Walden, Charité-
Universitätsmedizin-Berlin 
 
Malaria (n=10) 
VL (n=26) 
VL/HIV (n=11) 
VLS (n=13) 
 
South France 
(n=75) 
Prof. Renaud Piarroux, 
University of the 
Mediterranean, Marseille-
France ASC (n=25) 
Total   324 
 
Abbreviations: VL, visceral leishmaniasis; TB, pulmonary tuberculosis; VLS, VL 
suspect; VL/HIV, VL/HIV co-infection; ASC, asymptomatic cases. Healthy control sera 
from Sudan included 20 of individuals from a non-endemic area (non-endemic control, 
NEC) and 30 from the same endemic area (endemic control, EC) as VL sera. Healthy 
sera from India were from the same endemic area (endemic control, EC). 1 Some sera 
were collected from non-endemic area, as described in section 2.1.11.  
 
 
 
2- Materials and Methods 
 
 41 
Dog sera: 
 
 
A total of 200 serum samples of symptomatic, asymptomatic and healthy dogs 
were included. Sera were collected in 3 endemic regions of canine visceral 
leishmaniais (CVL) in Portugal, Brazil and Croatia (Table 2.7). Sera included 9 
samples of confirmed CVL and 21 symptomatic cases (SC) of unconfirmed 
diagnosis. Dogs were considered symptomatic if they showed at least one of 
the common symptoms. Confirmation of diagnosis was based on detection of 
Leishmania amastigotes in stained lymph node (popliteal or prescapular) 
smears. 168 sera were from asymptomatic cases (ASC) from the same 
regions. Control samples included 20 sera of healthy dogs from Croatia. These 
sera were used to calculate ELISA cut off value. Dogs were clinically and 
parasitologically evaluated at the time of diagnosis and serum samples were 
collected. In addition, sera were also tested for the presence of anti-
Leishmania-specific antibodies using the direct agglutination test (DAT) or 
indirect immunofluorescence antibody test (IFAT) as previously described 
(Martinkovic and Marinculic, 2006).  
 
Table 2.7: Origin and number of dog sera: 
 
Origin 
(no. of sera) 
Supplier Clinical 
condition 
(no. of sera) 
 
CVL (n=9) 
Évora, South 
Portugal 
(n=27) 
Dr. Saul Santos,  
Department of veterinary medicine, 
University of Évora, Portugal 
 
SC (n=18) 
 
SC (n=3) 
 
 
 
 
Caicó Paraíba, 
Brazil 
(n=16) 
Prof. Paulo Andrade, Department of 
Genetics, Federal University of 
Pernambuco, Recife, Brazil. 
         & 
Dr. Maria Melo,  
Laboratory of Molecular Genetics and 
Immunology, Federal University of 
Campina Grande, Patos, Paraíba, Brazil. 
 
ASC (n=13) 
 
ASC (n=137) 
Croatia 
(n=157) 
Dr. Franjo Martinkovic, 
Department for Parasitology and Parasitic 
Diseases, faculty of Veterinary Medicine 
University of Zagreb 
 
Healthy (n=20) 
Total  200 
 
CVL, canine visceral leishmaniais; SC, symptomatic cases; ASC, asymptomatic cases. 
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2.1.12 Commercial recombinant antigen and serological tests: 
 
Recombinant K39 antigen: 
Recombinant lipoprotein antigen rK39 of L. infantum (synonym. L. chagasi) 
was purchased from Rekom Biotech, S.L., Granada Spain. It contains 
repetitive immunodominant epitopes of kinesin-related protein. It was 
expressed as 6 x His-tagged His-rK39 fusion protein at the C-terminus of the 
kinesin-related protein with 100% identity with the accession number 
AAA29254.1. Upon receipt, the protein concentration was verified as described 
for rKLO8 protein (see section 2.2.9). Aliquots were kept at -80°C. 
 
rK39 strip test: 
Individual IT LEISH dipstick kits using recombinant K39 antigen (Burns et al., 
1993) for detection of human VL antibodies were purchased from Bio Rad, 
France. The test was performed and interpreted as recommended by the 
manufacturer. Sera were considered positive when a dark purple control band 
appeared. Samples with invalid results were repeatedly tested. 
 
rKE16 rapid test (Signal-KA): 
Signal KA flow through test kit, purchase from Span Diagnostics Ltd (Surat, 
India), was used for qualitative determination of Leishmania-specific 
antibodies. The test is based on the recombinant KE16 antigen of L. donovani 
KE16 strain isolated in India (Sivakumar et al., 2006). Test were performed and 
interpreted as described by the manufacturer. Briefly, 50 µL of patients' serum 
diluted 1:5 was added onto a nitrocellulose membrane which has been 
immobilised with the recombinant antigen. Sera were allowed to soak 
completely before carrying out the next step. The test was read within 10 
minutes. Sera were considered positive if two magenta red dots, one for 
control and other for test, appeared. A single dot in the control area indicated a 
negative result. In the absence of a control dot, tests were considered invalid.  
 
Direct agglutination test, DAT: 
The DAT (ITMA-DAT/VL) kits (Lot 11D1B1) were purchased from the Institute 
of Tropical Medicine, Antwerp-Belgium (ITMA). The antigen is a freeze-dried 
suspension of trypsin-treated, fixed and stained promastigotes of L. donovani 
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strain 1-S (Harith et al., 1988; Meredith et al., 1995). The test was performed in 
96 V-shape microplates (Greiner BioOne, Germany) according to the 
manufacturer’s instructions. Besides internal controls, positive and negative 
pooled sera were included in each plate and results were read after overnight 
incubation at R/T. Samples with titres of 1:>3200 were considered positive, 
whereas samples with titres of 1:800 and 1:1600 were considered as 
borderline and were repeated.  
 
Table 2.8: Overview of Leishmania antigens and parasites used in the serological 
tests: 
 
Test Antigen Parasite Source 
rKLO8 ELISA rKLO8 L. donovani LO8 This study 
rK39 ELISA rK39 L. infantum LEM 589 Rekom Biotech, Spain  
IT LEISH rK39 L. chagasi BA-2 Bio Rad, France 
Signal-KA rKE16 L. donovani KE16 Span Diagnostics, India 
ITMA-DAT/VL DAT L. donovani 1S ITMA, Belgium 
 
DAT, direct agglutination test; ITMA, Institute of Tropical Medicine, Antwerp; VL, 
visceral leishmaniasis.  
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2.2 METHODS: 
 
2.2.1 Leishmania culture:  
 
L. donovani reference strain LO8 was kindly provided by Prof. Bernhard 
Fleischer, Bernhard Nocht Institute for Tropical Medicine (BNITM), Hamburg. 
The strain was originally isolated in Sudan from a confirmed case of visceral 
leishmaniasis. The parasite was cultured at 28°C in  RPMI-1640 supplemented 
with L-glutamine, NaHCO3 (Sigma-Aldrich) and 10% (v/v) fetal calf serum 
(Sigma-Aldrich).  
 
2.2.2 Isolation and purification of Leishmania genomic DNA:  
 
Genomic DNA was isolated from L. donovani LO8 culture using Gentra 
Puregene Cell Kit.  
 
Protocol: 
• Add 20 million cells in culture medium to a 1.5 ml microfuge tube. 
• Centrifuge at 13,000 x g for 5 min. to pellet cells. Remove supernatant leaving 
behind 10-20 µl residual liquid.  
• Pour off supernatant and resuspend cells in remaining liquid by vortexing. 
• Add 300 µl Cell Lysis Solution to the resuspended cells and pipet up and 
down.   
• Add 1.5 µl RNAse A (10 mg/ml) and mix the sample by inverting the tube 25 
times.  Incubate at 37°C for 30 min.  
• Add 100 µl Protein Precipitation Solution to the cell lysate. 
• Vortex vigorously at high speed for 30 seconds. 
• Centrifuge at 13,000 x g for 1 min. to pellet proteins. 
• Pour supernatant into a fresh 1.5 ml microfuge tube containing 300 µl 
isopropanol and invert 50 times to precipitate genomic DNA. 
• Centrifuge at 13,000 x g for 1 min. to pellet the DNA.   
• Discard the supernatant and add 300 µl 70% ethanol and invert the tube 
several times to wash the DNA.  Invert the tube until the pellet is no longer 
stuck to the tube. 
• Centrifue at 13,000 x g for 1 min. to pellet DNA.  Discard supernatant and 
allow to air dry. 
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• Rehydrate DNA in 50 µl water and incubate at 65°C for 1 hr then store at -
20°C.  
 
2.2.3 Polymerase chain reaction (PCR): 
 
Partial gene fragment encoding the immunodominant repeats of L. donovani, 
designated KLO8, was amplified from promastigote genomic DNA using the 
forward (5'-GAGCTCGCAACCGAGTGGGAGG–3´) and reverse (5'- 
GCTCCGCAGCGCGCTCC–3') primers,  designed according to the published 
L. chagasi gene for kinesin-related protein (GenBank: L07879.1). PCR reaction 
was performed using Phusion® High-Fidelity DNA Polymerase (FINNZYMES 
OY, Finland) in a total volume of 50 µl, containing 3 % (v/v) DMSO, 10µl HF 
buffer, 10mM dNTPs mix-OLS (OMNI life science) and 100 ng genomic DNA. 
Concentration of DNA was measured by NanoDrop 1000 spectrophotometer 
(peQLab). 
 
Table 2.9: PCR protocol (Phusion® high-Fidelity DNA polymerase):  
 
Component Volume /50 µl  Final concentration 
H2O 28 µl - 
5X Phusion HF buffer 10 µl 1 x 
10 mM dNTPs 1 µl 200 µM 
Primer 1 2 µl 0.5 µM 
Primer 2 2 µl 0.5 µM 
Template DNA 5 µl 100 ng 
DMSO 1.5 µl 3% 
Phusion DNA polymerase 0.5 µl 0.02 U/µl 
 
 
 
 
 
 
 
 
 
 
2- Materials and Methods 
 
 46 
Cycling condition: 
 
Cycle step Temp. Time Cycles 
Initial denaturation 98oC 30 sec. 1 
Denaturation 98oC 10 sec. 
Annealing 61.0 – 71.0oC 20 sec. 
Extension 72.0oC 20 sec. 
 
25 
Final extension 72.0oC 
4oC 
5 min. 
Hold 
1 
 
2.2.4 Agarose gel electrophoresis: 
 
The DNA was separated by electrophoresis and visualized by ethidium 
bromide. 
 
Preparing 1% (w/v) agarose gel: 
•  Take 1 g agarose powder and add it to a 250 ml flask 
•  Add 100 ml TBE or TAE Buffer to the flask.  
•  Melt the agarose in a microwave until the solution becomes clear.   
•  Let the solution cool to about 55-60°C.   
•  Pour the melted agarose solution into the casting tray and let cool until it is 
solid. 
•  Pull out the combs and remove the tape.   
•  Place the gel in the electrophoresis chamber. 
•  Add enough TBE or TAE Buffer over the gel (about 2-3 mm). 
 
Protocol: 
•  Add 6X Sample Loading dye to an appropriate volume of PCR reaction  
• Carefully pipette 10 µl of each sample/Sample Loading dye mixture into 
separate wells in the gel. 
•  Pipette 5 µl of the DNA ladder standard into one well of each row on the gel. 
•  Run at 100 - 120 volts. 
•  Stain with 0.5 mg/ml ethidium bromide for about 20 minutes. 
 
2.2.5 DNA ligation and restriction digestion: 
 
KLO8 of L. donovani (883bp) was gel purified, digested with EcoRV and 
cloned into the plasmid vector pcDNA3.1(+) (Invitrogen life technologies, USA) 
2- Materials and Methods 
 
 47 
generating the non-tagged KLO8 construct, pcDNA/KLO8. Protocols were 
according to the manufacturer’ instructions and as follow: 
 
Restriction digestion protocol (Invitrogen): 
• EcoRV                                1 µl 
• 10X Buffer H                      2 µl 
• Substrate DNA                  10 µl (~ 200 ng) 
• Sterile water                      17 µl 
• Incubate at 37°C for 30 mins. 
 
Buffer Compositions: 
10X Buffer H 
- 500 mM Tris-HCl, pH 7.5 
- 100 mM MgCl2 
- 10 mM Dithiothreitol (DTT) 
- 1000 mM NaCl 
 
Gel clean-up (Macherey- Nagel): 
• Excise gel slice containing the DNA fragment and determine its weight. 
• For each 100 mg of agarose gel add 200 µl buffer NT. 
• Incubate at 50°C for 5-10 min. 
• Load into the extraction column and centrifuge for 1 min at 11,000 x g. 
Discard flow-through. 
• Add 600 µl buffer NT3 and centrifuge for 1 min at 11,000 x g. Discard 
flow-through. 
• Centrifuge 2 min at 11,000 x g and incubate 2-5 min at 70°C. 
• Add 15-50 µl water and incubate at R/T for 1 min. Centrifuge for 1 min at 
11,000 x g. 
Vector Dephosphorylation Protocol (New England Biolabs): 
•    10X Antarctic Phosphatase Reaction Buffer       3 µl 
•    Vector DNA cut with restriction enzymes            25.5 µl (1 µg) 
•    Antarctic Phosphatase                                        1.5 µl (5 units). 
Incubate for 30 min. at 37°C. Heat inactivate for 5  minutes at 65°C. 
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Ligation protocol (New England Biolabs): 
•    10X T4 DNA ligase buffer                                   2 µl 
•    Dephosphorylated vector DNA                          10 µl (50 ng) 
•    Gel purified and cleaned PCR product               6 µl 
•    T4 DNA ligase                                                    1 µl 
•    Mix reaction tubes by pipetting up and down. Incubate at 16°C for overnight. 
 
Preparation of competent E. coli cells:  
             To allow uptake of DNA, E. coli cells were manipulated with rubidium chloride 
method as following: 
• Prepare 2 ml O/N LB culture at 37°C. 
• Inoculate 5 ml LB broth with 500 µl O/N culture and shake at 37°C until 
OD600 reach 0.6-0.7 (3.3 McFarland ‘mcf’).  
• Centrifuge 8 min at 1880 x g at 4°C. 
• Resuspend the pellet in 33 ml RF1 buffer and incubate for 15 mins on ice. 
•  Centrifuge 8 min at 1880 x g at 4°C. 
• Resuspend the pellet in 5 ml RF2 buffer and incubate 15 mins on ice.  
• Put 100 µl aliquots in a liquid nitrogen container then store at -80°C.  
 
2.2.6 Transformation of E. coli: 
 
The recombinant DNA was transformed into Top10 E. coli cells and cultured 
on LB agar containing 100 µg/mL ampicillin as a selective agent.  
 
Protocol:  
• Thaw a vial (100 µl) of competent E. coli on ice. 
• To the aliquots add content of a ligation tube or 100 – 200 ng plasmids.  
• Incubate 30 min on ice.  
• During this time pre-heat water bath to 42°C and wa rm 2 ml LB broth 
medium at 37°C in a 15 ml Falcon tube.  
• Incubate samples at 42°C in water bath for exactly  90 sec.  
• Immediately transfer samples on ice, leave for 1-2 minutes.  
• Add 900µl of LB medium to each sample.  
• Incubate at 37°C for 60 minutes with shaking at 20 0 rpm.  
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• Centrifuge samples for 5 min at 2000 rpm and discard supernatant.  
• Plate 100 µl of bacterial pellet on LB agar plate with ampicillin (100 µg/ml) 
and kanamycin (25 µg/ml). Incubate plates at 37°C f or overnight.   
2.2.7 Isolation of plasmid DNA and sequence analysis: 
 
Recombinant plasmids were isolated by plasmid DNA purification method 
(Macherey-Nagel). DNA inserts were confirmed by restriction digestion 
(Fermentas GmbH, Germany) and by sequence analysis using extended 
HotShot sequencing reactions at Seqlab-Sequence Laboratories Göttingen 
GmbH. Each insert was sequenced at least twice. Digested plasmids were 
resolved by agarose gel electrophoresis and visualized with ethidium bromide. 
 
Restriction digestion protocol (Fermentas): 
• PCR product            2 µl 
• BamH1                     1 µl   (5 minutes) 
• Sal1                          1 µl   (60 minutes) 
• 10X Buffer                2 µl 
• Sterile water             14 µl 
      Incubate at 37°C.  
 
2.2.8 Protein expression: 
 
For expression of the recombinant protein, KLO8 was subcloned into the His-
tag vector pQE41 (Qiagen GmbH, Germany). The DNA construct 
pcDNA/KLO8 was used as template with the forward (5'-
GTGGAATTCTGCAGATGGATCCATGGAGCTCGCAACC–3´) and reverse (5'-
GCCGCCACTGTGCTGGATGTCGACGCTCC–3´) primers. For amplification of 
the entire tandem repeats of KLO8, primers were designed to contain an extra 
bases sequence at the 5´ end of the primers overhang specific sequence of the 
vector. Primers included also restriction sites BamHI and SalI (underlined) 
(Fig. 2.2).  
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Fig. 2.2 PCR strategy for amplification of KLO8 tandem repeats: 
 
 
Amplification was performed using Phusion® Hot Start II DNA Polymerase 
(Thermofisher Scientific, USA) as recommended by the manufacturer. 
Amplified DNA fragments were digested with the same restriction enzymes and 
cloned in-frame and down stream of 6x His-tag into the corresponding sites of 
the vector pQE41 to generate the plasmid construct carrying the target gene, 
named as pQE41/KLO8. The recombinant plasmid was verified by DNA 
sequencing and restriction analysis and then transformed into competent M15 
E. coli cells (Qiagen GmbH, Germany). E. coli were grown at 37°C in Luria-
Bertani (LB) medium containing 100 µg/ml ampicillin (Sigma-Aldrich, Germany) 
and 25 µg/ml kanamycin (Sigma-Aldrich, Germany) to a optical density (OD600) 
of 0.8 (BioPhotometer, Eppendorf). Recombinant protein expression was 
induced by adding 1mM isopropyl β-D-thiogalactoside (IPTG; Roth, Germany) 
for 4 hours. E. coli cells were harvested by centrifugation at 3340 g for 10 min 
at 4°C. Bacterial pellets were then lysed in PBS (p H 7.4) containing 0.25 mg/ml 
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lysozyme (Roth, Germany), 25 U/ml benzonase nuclease (Novagen, 
Germany), 10 mM imidazol (Roth, Germany), 1 mM PMSF (Sigma, USA) and 
2µM β-mercaptoethanol (Sigma, USA). Subsequently, bacterial lysates were 
sonicated 6 times (Bandelin Sonorex, Germany) on ice for 10 seconds each 
with >10 seconds rest and stored at -20°C. The rKLO 8 was expressed as 6 x 
His-tagged His-rKLO8 fusion protein and was recovered in the soluble 
fraction of the bacterial lysate by SDS-PAGE.  
 
Table 2.10: PCR protocol (Phusion® Hot start II high-Fidelity DNA polymerase):  
 
 Component Volume /50 µl Final conc. 
H2O 28.5 µl - 
5X Phusion GC buffer 10 µl 1 x 
10 mM dNTPs 1 µl 200 µM 
Primer 1 2.5 µl 10 pmol/µl 
Primer 2 2.5 µl 10 pmol/µl 
Template DNA 5 µl 100 ng 
Phusion DNA polymerase 0.5 µl 0.02 U/µl 
 
Cycling condition: 
Cycle step Temp. Time Cycles 
Initial denaturation 98oC 30 sec. 1 
Denaturation 98oC 10 sec. 
Annealing 61.0 – 71.0oC 20 sec. 
Extension 72.0oC 30 sec. 
 
35 
Final extension 72.0oC 
4oC 
10 min. 
Hold 
1 
 
 
2.2.9 Protein purification: 
 
Purification was carried out using nickel nitrilotriacetic (Ni-NTA) columns 
(Qiagen GmbH, Germany). The supernatant was loaded into a Ni-NTA column, 
which was pre-equilibrated with PBS, pH 7.4, containing 10 mM imidazole, 
1 mM PMSF and 2 µM β-mercaptoethanol. The recombinant protein was 
eluted with the same buffer containing 400 mM imidazole. Salts and imidazole 
were removed by dialysis in PBS buffer. Protein concentration was determined 
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using the Bradford assay compared to bovine serum albumin (BSA) as 
standard. Protein aliquots were kept at -80°C.  
 
Large-scale Culture Growth for Protein Expression: 
1. Inoculate 2 ml of LB broth containing 100 µg/ml ampicillin and 25 µg/ ml 
kanamycin from a fresh plate with expression-vector strain. Grow O/N at 37°C 
with shaking.  
2. Inoculate 400 ml (X2) of antibiotic-containing media with 400 µl from the 2 ml 
culture (1:1000 dilution of starter culture). Grow at 37°C with shaking at 150 rpm 
until OD600 reach 0.8 (~ 3 hrs). 
3. Collect 50 ml to be used as non-induced fraction. 
4. Induce protein synthesis by adding 400 µl IPTG 1M (final conc. 1 mM). Incubate 
for 4 hrs at 37°C with shaking. 
5. Collect pellet by centrifugation for 10 min. at 3300 x g in 50 ml falcon tubes. 
6. Wash with cold PBS and repeat centrifugation X1. 
7. Freeze pellet at -20°C and thaw (pellets can be stored frozen for the following 
day).  
8. For each pellet from 400 ml culture, add: 
• 10 ml 10 mM imidazol buffer (lysis), vortex 1 min 
• 20 µl 0.1 M PMSF  
• 2 µl benzonase nuclease (Novagen) 
• 20 µl lysozyme (stock 25 mg/ml) 
9. Mix well and incubate 1 hr at 4°C with shaking a t 350 rpm. 
10. Freeze and thaw X3 at -20°C. 
11. Sonicate (in glass bottles) 6X for 10 s with > 10 s rest at 4°C. 
12. Freeze and thaw X1. 
13. Centrifuge at 16400 x g for 30 mins at 4°C in e ppendorf tubes. 
14. Collect supernatants and pellets.    
15. Add supernatant to ~ 2 ml Ni- agarose beats column previously 2-3 X washed 
with water to remove ethanol and equilibrated 2-3 X  with 10 ml 10 mM imidazol 
buffer. 
16. Collect flow-through (unbound fraction). 
17. Wash with 15 ml 20 mM imidazol buffer, collect wash (wash fraction 1). 
18. Wash with 15 ml 60 mM imidazol buffer (wash fraction 2).  
19. Elute with 10 ml 400 mM imidazol buffer and collect 1-1.5 ml fractions. 
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2.2.10 SDS-polyacrylamide gel electrophoresis (PAGE) and Western blot 
(WB) analysis: 
 
Fractions of bacterial cell lysates or the purified protein were loaded on a 12% 
SDS-PAGE under denaturing conditions (Laemmli, 1970) and then stained with 
Coomassie Brilliant Blue G250 (Merck KGaA, Germany) or transferred to a 
nitrocellulose transfer membrane (Whatman GmbH, Germany) using the Bio-
Rad Semi-dry Trans-Blot at 200 mA for 1hr. The membrane was blocked with 
5% BSA (w/v) in 100 mM NaCl, 0.05% Tween 20 (v/v) and 10 mM Tris-HCl, pH 
7.4 (blocking buffer) and subsequently incubated for 18 hrs at 4°C with sera 
from  patients– or healthy controls, diluted 1:1000 in blocking buffer. After 
washing, blots were incubated for 1 hr at room temperature (R/T) with 
Peroxidase-conjugated Donkey Anti-Human IgG (H+L) (Jackson 
Immunoresearch Laboratories, USA) diluted 1:10000. The protein bands were 
revealed with Maximum Sensitivity Substrate system (Thermo Scientific, USA). 
 
2.2.11 ELISA: 
 
The optimal protein concentration and serum dilutions were determined using 
10 pooled VL sera and 10 control sera from non-endemic areas in Sudan. To 
select optimal conditions for the discrimination between positive and negative 
sera, protein concentrations were titrated against serial dilutions of positive or 
negative sera. MaxiSorp™ high protein-binding capacity polystyrene 96 ELISA 
plates (NUNC TM Serving Life Science, Denmark) were used. Protein 
concentrations of 5 - 50 ng/well were tested for coating ELISA plates overnight 
at 4°C in 0.1 M NaHCO 3 buffer, pH 9.6.  Plates were washed with PBS 
containing 0.05% (v/v) Tween-20 and then blocked with 3% (w/v) BSA, in the 
same buffer at R/T for 1-2 hours. After additional washes, 50 µl diluted positive 
or negative serum samples were added to each well, and plates were 
incubated at R/T for 45 minutes. After washing, 50 µl/well peroxidase-
conjugated AffiniPure Donkey anti-Human IgG (H+L) or rabbit anti-Dog IgG 
(H+L), diluted 1:10000, were added to each well and plates were incubated at 
R/T for further 1 hr. Colour was developed with hydrogen peroxide and 
tetramethylbenzidine (R&D Systems, USA). Reaction was stopped with 2N 
sulfuric acid after 10 minutes incubation in the dark. The optical density (OD) 
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was measured at 450 nm using an ELISA microreader (FLUOstar Omega, 
BMG LABTECH). Each sample was run in duplicates and the mean of 
absorbance values were calculated. Samples showing invalid or inconsistent 
results were repeated.  
As control, pooled positive and negative sera were included in each plate, 
when testing individual sera.  
 
2.2.12 Bioinformatics analysis: 
 
Amino acid sequence of KLO8 was determined with the ExPASy Proteomics 
Server of the Swiss Institute of Bioinformatics (http://web.expasy.org/translate/) 
and was compared with published sequences obtained from the National 
Centre for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). Amino 
acid sequence of KLO8 was aligned with published kinesin-related proteins of 
seven strains belonging to L. donovani subspecies using ClustalW2-Multiple 
Sequence Alignment (http://www.ebi.ac.uk/Tools/msa/clustalw2/). Homology 
search performed with BLASTP 2.2.1 showed that KLO8 has the highest 
identity with an amino acid fragment encoded by the 756 bp repeat of K39 
kinesin protein of L. donovani 1S (2564-3319). Therefore, this region was used 
in the alignment. Immunodominant repeats of KLO8 (294 AA), K39 (252 AA) 
and KE16 (155 AA) were also aligned. DNA sequence of KLO8 was analyzed 
to locate and display tandem repeats using Tandem Repeats Finder 
(http://tandem.bu.edu/trf/trf.html) (Benson, 1999). Nucleotide and amino acid 
sequences have been deposited in GenBank (accession numbers KC788285 
and AGL98402) using Sequin software tool (http://www.ncbi.nlm.nih.gov/ 
Sequin/). 
 
2.2.13 Statistical analysis: 
 
Data were analyzed using GraphPad Prism software (GraphPad Prism Inc., 
San Diego, Ca). Significance of antibody responses was assessed using 
unpaired Student t test or one way ANOVA test and p values < 0.05 were 
considered significant. Cut off values for each recombinant protein were 
defined as mean absorbance values of 30 sera of healthy controls from Sudan 
or 20 dogs’ sera from Croatia plus 3 standard deviations (SD). Sensitivity, 
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specificity, positive predictive value (PPV) and negative predictive value (NPV) 
were calculated to assess usefulness of the diagnostic assays at 95% 
confidence intervals. Sensitivity was defined as the percentage of serum 
samples of confirmed human or canine VL with positive test results. Specificity 
was assessed as percentage of total serum samples from non-VL cases with 
negative test results. This group included healthy controls, malaria-, TB-, 
toxoplasmosis-, and leukemic patients. PPV was calculated as number of true 
positives divided by the number of true positives and false positives. NPV was 
calculated as number of true negatives divided by the number of true negatives 
plus number of false negatives.  
 
Formulae:  
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3. RESULTS: 
 
3.1 Identification, characterization and serological evaluation of a novel L. 
donovani antigen rKLO8 for visceral leishmaniasis in Sudan: 
 
3.1.1 Identification and characterization of KLO8:   
A Partial gene fragment encoding immunodominant kinesin protein of L. 
donovani, designated KLO8, was amplified from promastigote genomic DNA 
from promastigotes using primers designed according to the published L. 
chagasi gene for kinesin-related protein (GenBank: L07879.1). The amplified 
products revealed multiple bands with sizes equivalent to 117bp repeats (Fig. 
3.1A). The largest amplification product was digested with EcoRV and cloned 
into the corresponding site of the plasmid vector pcDNA3.1(+) to make the 
nontagged KLO8 construct, pcDNA/KLO8. The insert was confirmed by 
restriction digestion with BamHI and XbaI (Fig. 3.1B) and by sequencing. 
Sequence analysis revealed a partial open reading frame of 883 bp, lacking 
the start codon ATG at the 5` end of the sense sequence.  
 
 
Fig. 3.1: Amplification and cloning of KLO8. Gene fragment encoding KLO8 of L. 
donovani was amplified and cloned into pcDNA3.1(+). (A) PCR products were resolved 
by agarose electrophoresis showed multiple repeat bands equivalent to 117 bp 
repeats. Lanes 1-3, DNA products amplified at 61.0 - 71.0°C; Lane M, 100 bp DNA 
Ladder. (B) Recombinant plasmid was isolated and screened by restriction digestion 
with BamHI and XbaI and resolved by agarose gel electrophoresis. Lane 1, digested 
plasmid carrying the KLO8 gene; Lane 2, empty vector digested with the same enzyme 
as control; M, 1 kb DNA Ladder. 
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Predicted amino acid (AA) sequence, generated with ExPASy (http://web. 
expasy.org/translate/), showed that KLO8 encodes a protein of 294 AAs with a 
predicted molecular mass of 32.4 kDa and isoelectric point (IP) of 4.39. 
Nucleotide sequence of KLO8 was submitted to GenBank under the accession 
number KC788285 (see Appendix). Homology search in protein database 
(http://www.ncbi.nlm.nih.gov/) showed that KLO8 protein contains putative 
conserved domains of significant similarity with kinesin proteins of strains 
belong to L. donovani subspecies (Table 3.1). KLO8 exhibited 93% and 88% 
AA identities with kinesin protein K39 of L. infantum (synonymous L. chagasi) 
strain BA-2 from Brazil (GenBank: AAA29254.1) and KE16 of L. donovani 
strain KE16 from India (GenBank: AAT40474.1), respectively. These two 
proteins are currently used in the known commercially available diagnostic 
rapid tests for VL. Of interest, KLO8 exhibited 97% identity with the kinesin 
protein Ldk39 of L. donovani 1S-CL2D from Sudan (GenBank: ABI14928.1), 
which however was never processed for development of a diagnostic test.  
 
Identities were high to moderate with other kinesin proteins of L. donovani, 
ranging from 90 – 69%. Moreover, an identity of 79% was found with K28 
fusion protein (GenBank: ADR74368.1), a synthetic protein construct derived 
from L. donovani, which consists of multiple tandem repeats of L. donovani 
haspb1 (hydrophilic acylated surface protein B1) and K39 of L. chagasi fused 
to the complete haspb2 protein (Pattabhi et al., 2010). The fact that there is still 
3% sequence variations between KLO8 and Ldk39 proteins, although derived 
from strains from the same region (Sudan), demonstrates that AA sequences 
of kinesin proteins vary even between different strains from the same region. 
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Table 3.1: Amino acid (AA) sequence identities of KLO8 (GenBank: KC788285) 
with similar published kinesin proteins of L. donovani: 
 
Strain Geographic origin 
of the strains 
AA identity GenBank no. 
L. donovani 1S 
 
Sudan 97% ABI14928.1 
L. chagasi BA-2 
 
Brazil 93% AAA29254.1 
L. donovani KE16 
 
India 88% AAT40474.1 
L. donovani DD81 
 
India 69% AAT40475.1 
L. donovani   Morena 
 
India 83% ABG43049.1 
L. donovani DD82 Bangladesh 90% BAF34578.1 
L. infantum  LON49 
 
Iran 90% ACF77142.1 
 
1 A WHO reference strain from India (MHOM/IN/DD8/1968). 2 L. donovani isolate from 
Bangladesh (Shamsuzzaman et al., 2000).  
 
3.1.2 Tandem repeats analysis of kinesin protein genes in Leishmania: 
 
Proteins containing tandem repeats are potential candidates for detection of 
immune responses against various parasites including Leishmania (Goto et al, 
2010). Thus, KLO8 was checked to determine whether it meets the tandem 
repeats (TRs) definition using Tandem Repeat Finder (http://tandem.bu.edu/ 
trf/trf.html). The program calculates an alignment score based on specific 
features such as period cycle of the repeat, copy numbers and percent of 
similarities between the repeats. TRs in other similar published protein genes 
of Leishmania were compared with those of KLO8 (Table 3.2). The K39 
kinesin protein gene (9831bp) of L. donovani 1S from Sudan showed 22 
tandem repeats of different period cycle. DNA fragment compose of 742 bp 
between nucleotide positions 2113 and 2854 showed higher identity with 
KLO8. This region was, therefore, used in the analysis.  
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Results showed conservation of a repeat of 117 bp in all L. donovani strains. 
Said 117 bp sequence encodes protein with 39 AA each. Copy number of 
repeats showed considerable variation among the different strains, which was 
higher in the strains from Sudan, Brazil and Bangladesh than Indian and 
Iranian strains. Importantly, tandem repeat score of L. donovani LO8 was 
higher (1299) than those of L. chagasi BA-2 and L. donovani KE16; 1276 and 
709, respectively. Since the level of protein immunogenicity depends to a 
greater extent on the period cycle and copy number of repeats and thus 
tandem repeat score, rKLO8 may therefore provide a significant contribution in 
evaluating immune responses to Leishmania.  
 
Table 3.2: Characteristics of tandem repeats in kinesin protein genes of 
Leishmania: 
 
Tandem repeats charactaristics 
 
 
Strains 
 GC- 
(%) 
Period 
Cycle 
(bp) 
Copy 
no. 
Similarity between 
repeats 
(%) 
 
Score 
L. donovani LO8 66 117 6.3 94 1299 
 
L. donovani 1S 67 117 6.3 91 1213 
 
L. chagasi BA-2 68 117 6.4 96 1276 
 
L. donovani KE16 68 117 4.0 91 709 
 
117 3.2 78 392 
117 3.1 77 356 
 
L. donovani DD81 
 
66 
234 1.9 80 523 
L. donovani Morena 67 117 3.9 92 798 
L. donovani DD82 69 117 7.4 97 1618 
 
L. infantum LON 49 68 117 3.0 92 575 
 
1 L. donovani strain (MHOM/IN/DD8/1968) from India (Sivakumar et al., 2008).  
2 L. donovani strain DD8 from Bangladesh (Shamsuzzaman et al., 2000). 
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3.1.3 Variation of AA composition in kinesin proteins of L. donovani: 
 
To identify differences in composition of amino acids in kinesin proteins of L. 
donovani, multiple sequence alignment was performed using ClustalW2-
Multiple Sequence Alignment (http://www.ebi.ac.uk/Tools/msa/clustalw2/). In 
this analysis aligned regions are jointed creating gaps to show the shared and 
variable regions. KLO8 was aligned with closely related kinesin proteins of 7 
Leishmania strains obtained from the National Centre for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov/). These strains represent L. donovani 
subspecies from the various endemic regions in Sudan, India, Bangladesh, 
Brazil and Iran. KLO8 showed the highest identity with a 252 AA sequence 
fragment of K39 kinesin protein of L. donovani 1S (GenBank: DQ831678.1). 
Therefore, this region was used in the analysis. As shown in Fig. 3.2, kinesin 
proteins of Leishmania are highly conserved across the examined strains. 
However, variation in amino acid composition was observed. Interestingly, 
none of these sequences showed complete homology, even between strains 
from the same areas (Sudanese and Indian strains).  
 
To identify differences within immunodominant epitopes of the three 
Leishmania antigens, KLO8 was aligned with AA repeats of K39 (GenBank: 
L07879.1) and KE16 (GenBank: AY615886.1). As shown in Fig. 3.3, 
immunodominant epitopes of the three antigens show presence of non-
conservative amino acids.  Differences in AA composition were highlighted in 
grey and identical regions were left unmarked. Altogether, these results 
confirm the variability in immunodominant repeats of kinesin proteins among 
different species and within the same species of L. donovani. 
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L. donovani-LO8          ELATEWEDALRERALAERDEAAAAELDAAASTSQNARESASERLTSLEQLLRESEERAGE 60 
L. donovani-1S           -----------------------------------------------EQLLRESEERAAE 13 
L. chagasi-BA2           ----------------------------------------------LEQQLRESEERAAE 14 
L. infantum-LON49        ---------------------------------------------------RES------ 3 
L. donovani-DD81               ELATEWEDALRERALAERDEAAAAELDAAASTSQNARESASERLTSLEQQLRESEERAVE 60 
L. donovani-KE16         ------------------------------------------------------------ 
L. donovani-RI           ------------------------------------------------------------ 
L. donovani-DD82            ---------------------------------------ELATEWEDALRERALAERDEA 21 
                                                     89 
L. donovani-LO8          LASQLESTTAAKMSAEQDRENTRATLEQQLRDSEERAAELASQLEATAAAKSSAEQDREN 120 
L. donovani-1S           LASQLESTTAAKMSAEQDRENTRATLEQQLRDSEERAAELASQLEATAAAKSSAEQDREN 73 
L. chagasi-BA2           LASQLEATAAAKSSAEQDRENTRATLEQQLRESEARAAELASQLEATAAAKMSAEQDREN 74 
L. infantum-LON49        -------------ACER-----LTSLEKQLRESEERAAELASQLEATAAAKSSAEQDREN 45 
L. donovani-DD81           LASQLESTTAAKMSAEQDRENTRAALEQQLRESEERAAELASQLEATAAAKSSAEQDREN 120 
L. donovani-KE16         --------------------------EQQLRDSEERAAELMRKLEATAAAKSSAEQDREN 34 
L. donovani-RI           ---------------------------QQLRDSEEHAAELKAQLESTAAAKTSAEQDREN 33 
L. donovani-DD82           AAAELDAAASTSENARESTSKLLTSVEQQLRDSETRAAELKAELEATAAAKTSVEQEREK 81 
                                                    :   :   :      :  :       .  :  : 
L. donovani-LO8          TRAALEQQLRDSEERAAELASQLESTTAAKTSAEQDRENTRATLEQQLRDSEERAAELAS 180 
L. donovani-1S           TRAALEQQLRDSEERAAELASQLESTTAAKTSAEQDRENTRATLEQQLRDSEERAAELAS 133 
L. chagasi-BA2           TRATLEQQLRDSEERAAELASQLESTTAAKMSAEQDRESTRATLEQQLRDSEERAAELAS 134 
L. infantum-LON49        TRATLEQQLRESEARAAELASQLEATAAAKSSAEQDRENTRAALEQQLRESEERAAELAS 105 
L. donovani-DD81                           TRAALEQRLRESEARAAELASQLEATAAAKSSAEQDRENTRAALEQRLRESEERAAELAS 180 
L. donovani-KE16         TRATLEQQLRESEEHAAELKAQLESTAAAKTSAEQDRENTRAALEQRLRESEERAAELAS 94 
L. donovani-RI           TRAALEQQFRESEEHAAELKAQLESTAAAKTSAEQDRENTRAALEQQLRESEERAAELMR 93 
L. donovani-DD82          TRTALEG-------RAAELARKLEATASAKNLVEQDRERTRATLEERLRIAEVRAAELAG 134 
                           ::          :      :  : ::    .         :  ::   :         
 
L. donovani-LO8          QLESTTAAKMSAEQDRENTRAALEQQLLESEERAGELASQLESTTAAKMSAEQDRENTRA 240 
L. donovani-1S           QLESTTAAKMSAEQDRENTRAALEQQLLESEERAAELKAELEATAAAKSSAEQDRENTRA 193 
L. chagasi-BA2           QLESTTAAKMSAEQDRESTRATLEQQLRESEERAAELASQLESTTAAKMSAEQDRESTRA 194 
L. infantum-LON49        QLESTTAAKMSVEQDRENTRAALEQ----------------------------------- 130 
L. donovani-DD81              QLEATAAAKSSAEQDRENTRPALEQQLRESEERAAELASQLEATAAAKSSAEQDRENTRA 240 
L. donovani-KE16         QLEATAAAKSSAEQDRENTRATLEQQLRESEARAAELASQLESTAAAKSSAEQDRENTRA 154 
L. donovani-RI           KLEATAAAKSSAEQDRENTRAALEQQLRESEEHAAELKAQLESTAAAKTSAEQDRENTRA 153 
L. donovani-DD82           VLEATAAAKTAVEQERERTRAALEQQLRESEARAAELAAQLEAAAAAKTSVEQERENTRA 194 
                           : :      :.         :        .:                                    
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L. donovani-LO8          ALEQQLRDSEERAAELASQLESTTAAKMSAEQDRENTRATLEQQLRDSEERAAE------ 294 
L. donovani-1S           ALEQQLRDSEERAAELASQLESTTAAKTSAEQDRENTRATLEQQLRDSEERAAE------ 247 
L. chagasi-BA2           TLEQQLRDSEERAAELASQLEATAAAKSSAEQDRENTRAALEQQLRDSEERAAELASQ-- 252 
L. infantum-LON49        ------------------------------------------------------------ 
L. donovani-DD81           ALEQQLRESEERAAELASQLEATAAAKSSAEQDRENTRAALEQQLRESEERAAELASQLE 300 
L. donovani-KE16         T----------------------------------------------------------- 155 
L. donovani-RI           T----------------------------------------------------------- 154 
L. donovani-DD82           TLEERLRLAEVRAAELAARLKSTAAVKSAMEQDRENTRAT-------------------- 234 
                                                                             
L. donovani-LO8          ------------------------------------- 
L. donovani-1S           ------------------------------------- 
L. chagasi-BA2           ------------------------------------- 
L. infantum-LON49        ------------------------------------- 
L. donovani-DD81           ATAAAKSSAEQDRENTRAALEQRLRESEARGAELASQ 337 
L. donovani-KE16         ------------------------------------- 
L. donovani-RI           ------------------------------------- 
L. donovani-DD82            ------------------------------------- 
 
 
 
Fig. 3.2 Sequence alignment of kinesin proteins of L. donovani. KLO8 was aligned with similar published proteins of 7 strains of L. 
donovani using ClustalW2-Multiple Sequence Alignment. These parasites included L. donovani 1S, L. chagasi BA-2, L. infantum LON 49, L. 
donovani DD81 isolated in Bangladesh, L. donovani DD82 from India, L. donovani KE16, and a recent isolate (RI) of L. donovani from India 
(GenBank numbers are shown in Table 3.1). K39 sequence fragment of L. donovani 1S that showed highest homology with KLO8 was 
used in this analysis. Dashed lines indicate gaps. Conserved amino acids were highlighted in black; (:), very similar; (·), similar. Length of 
each sequence is indicated at the 3’ end of the sequence. 
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Fig. 3.3 Sequence alignment of KLO8, K39 and KE16 antigens: Immunodominant 
repeats of KLO8 (294 AA), K39 (252 AA) and KE16 (155 AA) were aligned using 
ClustalW2-Multiple Sequence Alignment program. Different residues were highlighted in 
grey and identical were left unmarked. Dashed lines indicate gaps. 
 
3.1.3 Recombinant protein KLO8 as a suitable candidate for detection of 
Leishmania-specific antibodies:  
 
Since KLO8 differs from other Leishmania antigens, it was necessary to 
investigate its reactivity with sera of VL from Sudan. KLO8 was expressed as a 
His-tagged recombinant protein in M15 E. coli. Expression was confirmed by 
SDS-PAGE. As shown in Fig. 3.4A (lane 3), the apparent molecular weight of the 
His tagged fusion protein was 35kDa. The reactivity of purified recombinant 
protein rKLO8 was assessed in Western blot analysis using pooled sera from 10 
VL patients or 10 healthy controls. As shown in Fig. 3.4B, the positive sera 
recognized the recombinant protein (lane 2 & 3), while the negative sera did not 
(lane 1). These results demonstrate that the recombinant protein rKLO8 is 
suitable for detection of Leishmania-specific antibodies in sera of Sudanese VL 
patients.  
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Fig. 3.4 SDS-PAGE and western blot analysis. KLO8 was expressed as 6 x His-tagged 
protein in M15 E. coli and purified on a Ni-NTA column. (A) Protein expression was 
checked on a 12% acrylamide gel stained with Comassie blue; lane 1 and 2, bacterial 
lysates from uninduced or 1mM IPTG-induced cultures, respectively; lane 3, purified 
rKLO8; M, Protein ladder. (B) Reactivity of KLO8 was tested in WB analysis using 10 
pooled VL sera or 10 pooled healthy control sera from Sudan; lanes 1 and 2, lysates of 
IPTG induced cultures blotted with negative or positive sera, respectively; lane 3, purified 
rKLO8 blotted with positive sera; M, Protein ladder. 
 
3.1.4 rKLO8 ELISA for diagnosis of visceral leishmaniais: 
 
Next, an indirect IgG ELISA system using the recombinant protein rKLO8 was 
established for detection of Leishmania-specific antibodies in sera of VL patients 
from Sudan. As shown in Fig. 3.5, all tested protein concentrations (50-5 ng/well) 
were detected by pooled VL sera and did not cross-react with pooled sera from 
healthy individuals. ODs of positive sera were at least 4-fold higher compared to 
negative sera; however this ratio changed to much higher values when sera were 
more diluted. Coating ELISA plates with a concentration of 5 ng rKLO8 protein 
was sufficient for positive detection of sera from VL patients diluted up to 
1:25600. As a result of these titrations, a protein concentration of 5 ng/well and 
serum dilutions of 1:800 were selected and used as standard conditions in 
subsequent experiments. In some experiments, VL sera with negative results at 
1:800, were re-tested at a serum dilution of 1:100.  
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Fig. 3.5 Establishment of an indirect IgG ELISA for detection of Leishmania-
specific antibodies. For selection of the optimal ELISA conditions, 10 pooled VL or 
healthy control sera were titrated at serial twofold dilutions (1:25-1:25,600) and tested 
against different concentrations of the recombinant protein rKLO8. (A) 50 ng/100µl, (B) 
25 ng/100µl, (C) 10 ng/100µl, (D) 5 ng/100µl. Sera were tested in duplicates and means 
were taken.    
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3.1.5 Performance of rKLO8 and rK39 recombinant proteins for detection 
of IgG antibodies in Sudanese VL patients: 
 
The original assumption was that antibodies of VL patients from Sudan will better 
react with homologous proteins of L. donovani than the heterologous one of L. 
chagasi (K39). Thus, reactivity of the two recombinant proteins rKLO8 and rK39 
were evaluated in ELISA using individual human VL (n=106) and control (n=77) 
sera from Sudan. The recombinant protein rK39, obtained from Rekom Biotech, 
was expressed as 6 x His-tagged fusion protein in E. coli. To ensure similar 
conditions, rKLO8 was also expressed as 6 x His-tagged protein in E. coli. Sera 
of patients were diluted at 1:800 and tested on a protein concentration of 5 
ng/well.  
 
 
 
 
 
 
 
Quantitative analysis of antibodies in sera of VL to both recombinant proteins 
demonstrated significantly higher antibody levels than those of control subjects 
(P<0.0001) (Fig. 3.6A) although absorbance values among the patients` sera 
varied depending on the recombinant proteins. In general, sera tested on rKLO8 
yielded higher OD values than on rK39 with a mean value of 1.12+0.97 for rKLO8 
and 0.93+0.77 for rK39. In addition, sensitivity of rKLO8 was also increased with 
92.5% (98/106) for rKLO8 versus 86.8% (92/106) for rK39. Notably, none of the 
healthy or diseased controls (n=77) showed cross-reaction with either of the 
recombinant proteins.  
 
 
 
 
 
 
 
Sera of VL that were negative on rK39 or rKLO8 (n=14) were then retested and 
compared to control sera (n=77) at 1:100 serum dilution. As shown in Fig. 3.6B, 
retesting on rKLO8 yielded increased positive detection of VL patients (12/14) 
compared to rK39 (10/14) at cut-off values of 0.41 and 0.32 for rKLO8 and rK39, 
respectively. In addition, control sera tested on rKLO8 revealed less cross 
reactivity as compared to rK39. Both proteins showed cross reactivity with 3 sera 
from malaria patients and in addition rK39 showed false positivity with one 
healthy endemic individual.  These results demonstrate the increased reactivity 
of rKLO8 compared to rK39 in Sudan. Although the difference was not 
significant, it is likely that rKLO8 provides enhanced sensitivity for detection of 
Leishmania-specific antibodies in Sudan. Therefore, a rapid test based on rKLO8 
may be more sensitive for the detection of VL in Sudan and other East African 
countries where similar strains of L. donovani are endemic.  
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Fig. 3.6 Comparative reactivity of VL and control sera with rKLO8 and rK39 
recombinant proteins. The rKLO8 and rK39 proteins were used and compared in ELISA 
using protein concentrations of 5ng/100µl in 0.1M sodium carbonate. A panel of sera 
from VL patients and controls were tested.  Visceral leishmaniasis, VL (n=106), non-VL 
controls (n=77) including non-endemic healthy controls (NEC; n=20), endemic healthy 
controls (EC; n=30), malaria (MA; n=11), tuberculosis (TB; n=10), or leukaemia (LEU; 
n=6). (A) Sera were tested at dilutions of 1:800 and a cut off value (0.12) was established 
as means + 3 SD of 30 healthy controls from Sudan. (B) VL sera (n=14) with negative 
results at 1:800 were retested at a serum dilution of 1:100 and compared with the 
controls described in A. Cut off values were recalculated using 20 non-endemic healthy 
sera and found to be 0.41 and 0.32 for rKLO8 and rK39, respectively. Statistical analysis 
was performed using one way ANOVA nonparametric test. 
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3.1.6 Diagnostic performance of rKLO8- and rK39 ELISA and two 
commercial kits for diagnosis of visceral leishmaniais in Sudan: 
 
Using the same panel of VL and control sera, results of rKLO8- and rK39 ELISA 
were next compared with two commercial diagnostic kits, the rK39 rapid test and 
a freeze-dried version of DAT. As shown in Table 3.3, overall sensitivity of rKLO8 
(98.1%) was higher than that of rK39 (96.2%) when measured by ELISA. In 
comparison, the rK39 rapid test yielded sensitivity of 81.1% and DAT of 94.3%. 
With respect to specificity, rKLO8 ELISA showed slightly increased performance 
(96.1%) compared to the rK39 ELISA (94.8%) but lower than DAT (100%) and 
rK39 rapid test (98.7%). Accordingly, PPVs and NPVs were 97.2% and 97.4% for 
rKLO8 ELISA, 96.2% and 94.8% for rK39 ELISA, 98.9% and 79.2.9% for rK39 
rapid test and 100% and 92.8% for DAT, respectively.  
 
Interestingly, results of the four tests showed some discrepancies. Although 
tested positive in rKLO8 ELISA, 6 (5.7%) sera of the confirmed VL patients were 
negative (1:<1600) in DAT  (Fig. 3.7A). In addition, sera of 6 patients had weak 
DAT titres (1:3200-1:6400). On the other hand, while being positive in DAT, 4 
(3.8%) or 2 (1.9%) sera of VL patients were not detected by rK39 or rKLO8, 
respectively. Those 4 cases were also negative in the rapid test. However, VL 
sera with positive or negative DAT results reacted similarly with rKLO8 (Fig. 
3.7B), suggesting that rKLO8 and DAT react with different antibody specificities 
and thus monitoring different immune reactivities. Thus, a combination of both, 
rKLO8 ELISA and DAT provided 100% sensitivity for detection of VL. In addition, 
rKLO8 ELISA detected all VL sera that were positive in rK39 rapid test (Fig. 
3.7C), but sera negative in the rapid test displayed still low antibody reactivity 
when tested with rKLO8 (p<0.0001) (Fig. 3.7D).  
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Table 3.3 Diagnostic performance of rKLO8- and rK39 ELISA, rK39 rapid test 
(RT) and DAT for visceral leishmaniasis in Sudan: 
 
Sensitivity 
(n=106) 
Specificity 
(n=77) 
PPV NPV 
 
 
Test TP FN TN FP 
Estimated values at 95% CI 
 
 
rKLO8 
ELISA 
 
104 2 74 3 
 
98.1% 
 
96.1% 
 
97.2% 
 
97.4% 
 
rK39 
ELISA 
102 4 73 4 
 
96.2% 
 
94.8% 
 
97.2% 
 
94.8% 
 
rK39 
RT 
86 20 76 1 
 
81.1% 
 
98.7% 
 
98.9% 
 
79.2% 
 
DAT 100 6 77 0 
 
94.3% 
 
100% 
 
100% 
 
92.8% 
 
 
Abbreviations: TP, true positive; FN, false negative; TN, true negative; FP, false positive; 
PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval; 
DAT, direct agglutination test; ITMA, Institute of Tropical Medicine Antwerp. ELISA values 
were calculated combining results obtained at serum dilutions of 1:800 and 1:100. 
Detection of Leishmania in lymph node smears was used as reference. Specificity was 
calculated using 77 confirmed negative sera, including healthy controls, malaria -, TB-, 
and leukaemia patients. 
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Fig. 3.7 Reactivities of VL sera in rKLO8 ELISA, DAT and rK39 rapid test (RT).  ODs 
for 106 VL sera diluted 1:800 were measured in rKLO8 ELISA and compared with DAT 
antibody titres or rapid test results. (A) Sera were divided into 4 groups based on DAT 
titres; negative, 1:<1600; weak, 1:3200-1:6400; moderate, 1:12800-1:25600; strong, 
1:>51200. (B) Mean ODs of VL sera with negative or positive DAT titres. Results are 
expressed as mean + SD. (C) OD values of VL sera with negative or positive rapid test 
results. (D) Mean ELISA OD values of VL sera with positive or negative rapid test results. 
Dots represent values for individual sera and horizontal lines represent cut-off values. ns, 
not significant. 
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3.2 Performance of various serodiagnostic tests in three major endemic 
regions of visceral leishmaniais: 
 
3.2.1 Comparison of rKLO8 and rK39 for detection of Leishmania-specific 
antibodies: 
 
Since rKLO8 and rK39 show differences in reactivity with sera of VL from Sudan, 
we determined the performance of both proteins in other VL endemic regions. 
Antibody responses against recombinant proteins were measured and compared 
in ELISA using sera of VL and controls originated from India and France and 
were compared with those from Sudan. Protein concentrations of 5 ng and 1:800 
serum dilutions were used. Under these conditions, Leishmania-specific 
antibodies could be detected specifically in sera of VL from India and France, as 
well.  
 
Interestingly, individual OD values varied considerably among patients from the 
different geographical regions (Fig. 3.8). In contrast to patients' sera from Sudan 
and France, most sera of VL from India showed similarly high OD values. Out of 
26 VL sera from India, 25 (96.2%) showed OD values of more than 0.6 (5-fold cut 
of value) when tested in both rKLO8- and rK39 ELISA. These values were 33/50 
(66%) and 30/50 (60%) in sera of patients from Sudan with rKLO8 and rK39, 
respectively. Similar results were seen when both proteins were tested with sera 
from French VL and VL/HIV patients, yielding 18/26 (69.2%) and 6/11 (54.5%) 
positivity, respectively. Interestingly, 7 patients’ sera from Sudan and India 
showed higher ODs of > 2.15 to rKLO8 than rK39 (Fig. 3.8A & B). Such values 
however were not observed with sera from French patients (Fig. 3.8C). In 
general, sera of VL from India showed significantly increased reactivity to rKLO8 
and rK39 as compared to the patient groups from Sudan (p<0.0001) or France 
(p<0.0037) (Fig. 3.9). 
 
Among sera of symptomatic suspects (VLS), 9/11 (81.8%) from India and 10/13 
(76.9%) from France showed positive signals in the two ELISAs and thus were 
considered potential positives (Fig. 3.8A & 3.8C). Unexpectedly, rKLO8 detected 
more asymptomatic cases from France than rK39; 7/25 (28%) and 3/25 (12%) 
(Fig. 3.8C). 
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Fig. 3.8. Detection of Leishmania-specific antibodies in sera from various regions 
using rKLO8 and rK39. Protein concentrations of 5 ng/100µl rKLO8 or rK39 were tested 
using sera of patients and controls from India (A), Sudan (B) and France (C). Sera were 
tested at dilutions of 1:800. A cut off value of 0.12 was used. VL, visceral leishmaniasis; 
VLS, VL suspects; HC, healthy control; MA, malaria; TP, toxoplasmosis; VL/HIV, VL and 
HIV, ASC, asymptomatic cases. The black horizontal lines represent cut off values. OD 
values of 0.6 (5-fold cut off value) and 2.15 are shown in dotted lines.   
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Fig. 3.9. Comparative reactivity of VL sera from various regions in rKLO8- and rK39 
ELISA. OD values of VL sera from Sudan (n=50), India (n=26), France with negative 
(HIV-, n=26) or positive (HIV+, n=11) HIV were diluted 1:800 and tested in rKLO8- or 
rK39 ELISA. Means OD values were compared using unpaired student t-test. Dots 
represent values for individual sera and horizontal lines represent cut-off values (0.12). 
ns, not significant. 
 
3.2.2 Performance of rKLO8- and rK39 ELISA in various endemic regions: 
 
Diagnostic performance of rKLO8- and rK39 ELISA were estimated and 
compared for each endemic region. Sensitivity, specificity, PPV and NPV were 
calculated using results of confirmed VL and negative control groups. Both tests 
showed high diagnostic performance in the three regions (Tables 3.4 - 3.6). 
Sensitivity was similar in India (96.2%) and France (100%) but different in Sudan, 
98% (49/50) for rKLO8 ELISA and 96% (48/50) for rK39 ELISA. Only one serum 
sample from Sudanese VL showed a false-negative result in rKLO8 and two with 
rK39. Among VL/HIV sera from France, sensitivity was markedly decreased to 
81.8%. Specificity values were similarly high in Sudan (100%) and India (96.6%). 
One serum of a healthy individual from an endemic area in India showed a strong 
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reactivity (OD > 1.0) with both proteins (Fig. 3.8A). No cross reactivity was seen 
with sera from malaria and toxoplasmosis patients. Thus, PPVs of the two tests 
were high in Sudan and India with 100% and 96.2% for rKLO8 and rK39, 
respectively. NPVs were 97.6% and 95.2% in Sudan but similar (96.6%) in India. 
Together, these results demonstrate the high sensitivity of rKLO8- and rK39 
ELISA for diagnosis of VL in immunocompetent subjects, with rKLO8 displaying 
increased reactivity in Sudan and India.            
 
3.2.3 Performance of rapid tests based on rK39 and rKE16 proteins:  
 
Qualitative detection of Leishmania-specific antibodies was assessed using two 
commercial rapid tests (RTs) based on rK39 and rKE16. Diagnostic performance 
for each of the two tests was calculated on basis of results obtained on sera from 
various endemic regions (Tables 3.4 - 3.6). Interestingly, only in India both tests 
showed similar high sensitivity of 96.2%. Sensitivity was low in Sudan and 
France, ranging from 88% to 88.5% (rK39 RT) and 64% to 73.1% (rKE16 RT), 
respectively. In case of VL patients co-infected with HIV (VL/HIV) sensitivities 
were further reduced; 81.8% for rK39 RT and 63.6% for rKE16 RT. Specificity of 
rKE16 RT was better than rK39 RT in Sudan (100% and 97.5%) and similar 
(96.6%) in India. One serum of a malaria patient from Sudan was tested positive 
with rK39 RT as well as a healthy subject from India showed also cross-reaction 
in the two tests. Therefore, PPVs were 97.8% for rK39 RT and 100% for rKE16 
RT in Sudan and 96.2% for both tests in India. NPVs were similar in India (96.6%) 
and 86.7% and 83.3% in Sudan for rK39 RT and rKE16 RT, respectively.  
 
With regard to symptomatic suspects (VLS), 81.8% (9/11) of the serum samples 
from India were tested positive in both tests. In France, rapid tests of rK39 
detected more cases with 10/13 and 7/13 positive results for rK39 and rKE16, 
respectively. With respect to asymptomatic patients, 3 sera showed positive 
reaction in rK39 RT but tested negative in rKE16 RT. These results show that 
rapid tests based on rK39 and rKE16 have a high sensitivity only in India, 
highlighting the need for developing better rapid tests for VL in Sudan and 
France.  
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3.2.4 Performance of DAT for detection of Leishmania-specific antibodies:  
 
Semi-quantitative analysis of Leishmania-specific antibodies was determined with 
DAT, which uses L. donovani strain 1S (from Sudan). Antibody titres were 
determined and compared in sera of VL from three regions. In general, patients 
from Sudan and India revealed increased antibody titres as compared to patients 
from France (Table 3.7). DAT titres greater than or equal to 1:51200 were 
observed in 86% and 92.3% of the sera from Sudan and India, respectively. Sera 
of patients from France showed relatively weak DAT titres, strong antibodies were 
found in 57.7% of patients with VL and in 36.4% co-infected with HIV. A high 
proportion (45.5%) of the later group revealed DAT titres of 1:100-1:800.  Such 
low titres were not observed in sera from Sudan but only in one serum of VL from 
India.  
 
Performance of DAT in various endemic regions was shown in Tables 3.4 - 3.6. 
Sensitivity was high in Sudan (94%) and India (96.3%) as compared to France 
(88.5% for VL and 54.5% for VL/HIV sera). No cross-reactivity was found in sera 
of healthy or diseased controls from Sudan. One healthy subject from India was 
tested positive with strong titre (1:>102400), resulting in 100% specificity for 
Sudan and 96.6% in India. Accordingly, PPV was better in Sudan (100%) than in 
India (96%) and NPVs were similar in the two regions (93% and 93.3%). Among 
symptomatic suspects (VLS), 81.8% of serum samples from India and 76.9% 
from France demonstrated positive results. In contrast, out of 25 asymptomatic 
cases from France, only one serum was tested positive. Altogether, these results 
clearly show that the DAT from TMIA is suitable for serodiagnosis of VL both in 
Sudan and India.  
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Table 3.4: Performance of diagnostic tests for visceral leishmaniais in Sudan: 
 
Performance index (%) at 95% CI 
 
 
Diagnostic 
Test Sensitivity 
 
Specificity 
 
PPV 
 
NPV 
 
rKLO8 ELISA 98% 100% 100% 97.6% 
 rK39 ELISA 96% 100% 100% 95.2% 
rK39 RT 88% 97.5% 97.8% 86.7% 
rKE16 RT 64% 100% 100% 67% 
DAT 94% 100% 100% 93% 
 
RT, rapid test; DAT, direct agglutination test; PPV, positive predictive value; NPV, 
negative predictive value.  
 
 
Table 3.5: Performance of diagnostic tests for visceral leishmaniais in India: 
 
Performance index (%) 95% CI 
 
 
Diagnostic 
test Sensitivity 
 
Specificity 
 
PPV 
 
NPV 
 
rKLO8 ELISA 96.2% 96.6% 96.2% 96.6% 
rK39 ELISA 96.2% 96.6% 96.2% 96.6% 
rK39 RT 96.2% 96.6% 96.2% 96.6% 
rKE16 RT 96.2% 96.6% 96.2% 96.6% 
DAT  92.3% 96.6% 96% 93.3% 
 
See Table 3.4 for abbreviations. 
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Table 3.6: Sensitivity of diagnostic tests for visceral leishmaniais in HIV-negative 
(VL) or HIV-positive (VL/HIV) cases from France: 
 
Sensitivity (%)  95% CI 
 
Diagnostic 
test 
VL VL/HIV 
rKLO8 ELISA 100% 81.8% 
rK39 ELISA 100% 81.8% 
rK39 RT 88.5% 81.8% 
rKE16 RT 73.1% 63.6% 
DAT  88.5% 54.5% 
 
Sensitivity was calculated separately for the two groups, VL and VL/HIV. RT, rapid test; 
DAT, direct agglutination test; PPV, positive predictive value; NPV, negative predictive 
value.  
 
 
Table 3.7: DAT antibody titres in sera of visceral leishmaniasis from the three 
endemic regions: 
 
Reciprocal DAT titres 
number positive (%) 
 
Origin of sera 
(no.) 
 
100-800 
 
1600 
 
3200-6400 
 
12800-25600 
 
>51200 
Sudan 
(n=50) 
 0 
(0%) 
3 
(6%) 
2 
(4%) 
2 
(4%) 
43 
(86%) 
India 
(n=26) 
 1 
(3.8%) 
1 
(3.8%) 
0 
(0%) 
0 
(0%) 
24 
(92.3%) 
HIV –ve 
(n=26) 
3 
(11.5%) 
0 
(0%) 
3 
(11.5%) 
5 
(19.2%) 
15 
(57.7%) 
 
France 
HIV +ve 
(n=11) 
5 
(45.5%) 
0 
(0%) 
1 
(9.1%) 
1 
(9.1%) 
4 
(36.4%) 
 
Data were expressed as number positive (%). DAT titres; 1: 100-800, negative; 1:1600, 
marginal; 1:3200-1:6400, weak; 1:12800-1:25600, moderate; 1:>51200, strong. 
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3.3 rKLO8 ELISA for serodiagnosis of canine visceral leishmaniasis (CVL): 
 
3.3.1 Detection of Leishmania-specific antibodies in sera of symptomatic 
and control dogs:  
 
The rKLO8 ELISA was further evaluated for detection of Leishmania-specific 
antibodies in sera of symptomatic and negative control dogs. The symptomatic 
group included 9 sera of parasitologically confirmed CVL cases from South 
Portugal and 21 sera of unconfirmed symptomatic cases (SC) from Portugal and 
Brazil. Control samples included 20 sera of healthy dogs from a known endemic 
area of CVL in Croatia. This group was used to determine the cut off value and 
found to be 0.12. rKLO8 ELISA was optimised using the same protein 
concentration (5 ng/well) and serum dilutions (1:800) as described for human 
sera. At these conditions, the differences between positive and negative sera 
were optimal. rKLO8 ELISA was compared to results of DAT which was 
performed at the time of diagnosis. As shown in Table 3.8, both tests were highly 
sensitive in positive samples, detecting all sera of confirmed CVL (100% 
sensitivity). In addition, high proportion of unconfirmed symptomatic cases tested 
positive in both tests, 7/18 (38.9%) and 2/3 (66.7%) with rKLO8 ELISA and 6/18 
(33.3%) and 2/3 (66.7%) with DAT, respectively. No cross reactivity was found 
with the negative control group, demonstrating 100% specificity. These findings 
indicate that rKLO8 has the potential for detection of Leishmania-specific 
antibodies in canine visceral leishmaniais. 
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Table 3.8: Detection of Leishmania-specific antibodies in sera of dogs using 
rKLO8 ELISA and DAT: 
 
% of samples positive 
(no. positive/total) 
Clinical condition 
(sera no.) 
 
Origin of sera 
rKLO8 ELISA DAT* 
CVL (n=9) Évora, South 
Portugal 
 
100% (9/9) 100% (9/9) 
SC (n=18) Évora, South 
Portugal 
 
38.9% (7/18) 33.3% (6/18) 
SC (n=3) Caicó Paraíba, 
Brasil 
 
66.7% (2/3) 66.7% (2/3) 
HC (n=20)** Croatia 
 
0 (0/20) nd 
 
CVL, canine visceral leishmaniais; SC, symptomatic cases with negative smear results; 
HC, healthy controls with negative immunofluorescence antibody test (IFAT); DAT, direct 
agglutination test; nd, not done.  
 
3.3.2 Diagnosing Leishmania infantum infections in asymptomatic dogs:  
 
Since L. infantum may causes subclinical infection in dogs, performance of 
rKLO8 ELISA for serodiagnosis of asymptomatic CVL was also assessed. 
Immunoreactivities of 130 sera of asymptomatic dogs from two endemic areas in 
Brazil and Croatia were assessed and compared to control sera. This group 
included 72 sera previously classified as having Leishmania-specific antibodies 
in immunofluorescent antibody test (IFAT) (>1:80) and 45 sera with negative 
IFAT titres (<1:80). Twenty sera of the healthy dogs from Croatia were included 
as controls.  As shown in Fig. 3.10, positive ELISA signals (ODs > 0.12) were 
obtained with most of asymptomatic sera from Brazil (9/13, 69.2%) and all IFAT 
positive sera from Croatia (72/72, 100%). As expected, signals were significantly 
higher than the controls (p < 0.0001). Importantly, Leishmania-specific antibodies 
were also detected in 12/45 (26.7%) sera with negative IFAT titres. These results 
indicate that rKLO8 ELISA is suitable for serodiagnosis of L. infantum infections 
in asymptomatic dogs in areas where CVL is endemic.   
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Fig. 3.10. Detection of Leishmania-specific antibodies in sera of asymptomatic 
dogs.  rKLO8 ELISA was assessed using sera of asymptomatic dogs from different 
endemic regions for CVL, 13 from Brazil, 72 with immunofluorescent antibody test 
positive  (IFAT+) titres and 45 with IFAT negative titres (IFAT-) form Croatia and 20 sera 
of healthy dogs. A cut off value of 0.12 was established as means of 20 healthy dogs 
from Croatia pus 3SD. The black horizontal line represent cut off value. Statistical 
analysis was performed by unpaired student t test. ns, not significant. 
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4. DISCUSSION: 
 
Although proved to be extremely useful for detection of VL in human and 
animals, all of the existing serological tests reveal discrepant diagnostic outcome 
in comparison with parasitological procedures (Zijlstra et al., 1992). The variable 
performance of these tests in various endemic regions has prompted research to 
focus on the genetic difference between Leishmania parasites that might have 
contributed to the different outcome of these tests. These research efforts have 
further helped in learning about variability and heterogeneity of Leishmania 
antigens and have subsequently stimulated development of better diagnostic 
tests.  
 
In this study, we investigated whether sera of VL patients react better with 
antigens of Leishmania donovani originating from the same endemic area 
(homologous antigen). This might explain the difficulties associated with VL 
diagnosis in certain geographical areas such as in Sudan. To address this 
problem, a new protein antigen of L. donovani from Sudan was expressed and 
used to evaluate homologous and heterologous antibody reactions of VL sera 
from human and dogs.  
 
4.1 rKLO8, a novel antigen for diagnosis of VL in Sudan: 
 
VL in Sudan is considered a major health problem in poor communities with 
limited resources where most patients don’t have access to standard health care 
facilities. Therefore, availability of a simple and fast diagnostic test is of crucial 
importance. Because of their simplicity and low cost, lymph node aspiration and 
direct agglutination test (DAT) are currently the main tests used for VL diagnosis 
in the Sudan (Abass et al., 2007; Babiker et al 2007; Gorski et al., 2010; Musa et 
al 2010).  
 
Despite the availability of several recombinant proteins for VL diagnosis, the 
existing rapid tests are mainly based on kinesin proteins, i.e. rK39 of L. infantum 
(synonymous L. chagasi) and rKE16 of L. donovani (Burns et al., 1993; 
Sivakumar et al., 2006). While these tests are quite effective in Brazil and India, 
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their use in East Africa is not satisfactory (Abass et al., 2006; Ritmeijer et al 2006; 
Cunningham et al 2012). Unfortunately, there seems to be little interest in 
developing improved diagnostic tools for VL, as the disease is endemic in most 
developing countries of the world (Mabey et al., 2004). Improving VL diagnosis in 
these countries requires identification and testing of new antigens from 
autochthonous strains of L. donovani.  
 
In this study, a new recombinant protein of L. donovani from Sudan, designated 
rKLO8, showed significant homology with kinesin proteins of Leishmania. As 
expected, rKLO8 showed very high sequence identity with the LdK39 protein of L. 
donovani strain 1S from Sudan that has never been used for diagnostic purposes. 
Coding sequence of rKLO8 contains a conserved tandem repeat of 117 bp, 
encoding a protein with 39 amino acids each. Proteins with such tandem repeats 
are more likely to be targets of immune responses and more immunogenic than 
non-tandem repeat proteins (Cowman et al., 1985; Burns et al., 1993; Goto et al., 
2006; Folgueira et al., 2010).  It is worth mentioning that tandem repeat scores of 
rKLO8, rK39 and rKE16 were greater than 500, a cut off value to eliminate genes 
with small repeat domains (Goto et al., 2010). But rKE16 has relatively low score 
compared to rKLO8 and rK39, implying thus less conserved domains and 
subsequently weaker immunogenicity.     
Importantly, immunodominant epitopes of the 3 common Leishmania antigens 
show marked variations (Fig. 3.3). One can therefore assume that antigenic 
variation will most likely influence antibody reactivity in different regions which 
explains why use of rK39 and rKE16 was not optimal to provide reliable 
diagnosis in different endemic regions. Based on this assumption, the rKE16 
(antigen from an Indian strain of L. donovani) showed better performance for VL 
detection in India than in Brazil and East African countries (Cunningham et al., 
2012).  
 
Antigenic variation due to diversity of L. donovani sub-species has been 
proposed by others to be the cause for the low sensitivity in VL diagnosis based 
on rK39 (Sivakumar et al., 2008; Cunningham et al., 2012; Bhattacharyya et al., 
2013). Other authors have shown significant increase in the level of antibody 
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titres when homologous antigens of Leishmania were used in DAT compared to 
heterologous antigens (Garcez et al., 1997). Similar findings have been shown in 
ELISA using homologous L. chagasi or heterologous L. braziliensis antigens for 
detection of antibodies in symptomatic and asymptomatic dogs in Brazil (Ribeiro 
et al., 2011). However, it cannot be generalized that use of homologous antigens 
will always result in improved  diagnostic sensitivity, as sera of VL from 
Bangladesh reacted equally well with rK39 and rKRP42 derived from L. donovani 
from Bangladesh despite the marked heterogeneity of the two proteins (Tagaki et 
al., 2007). 
 
4.2 Performance of rKLO8 for VL diagnosis in Sudan: 
 
Diagnostic methods with high sensitivity for VL diagnosis are highly needed in 
Sudan to replace low sensitive tests based on the kinesin of L. infantum (rK39). 
Since rKLO8 differs from other Leishmania antigens, we investigated the 
influence of amino acid heterogeneity of the recombinant proteins on reactivity 
with VL sera from Sudan. The results clearly indicate that rKLO8 protein have 
increased reactivity with sera of Sudanese VL patients compared to rK39. This 
improvement is of particular importance for detection of VL at early or subclinical 
phases that are characterized by weak antibody responses. The decreased 
immune responses to rK39 observed in some of the VL patients from Sudan 
(Pattabhi et al., 2010) may explain the low sensitivity of rK39-based diagnostic 
tests in this region. This observation seems to be in accordance with our findings 
that VL sera with negative rK39 strip test results showed significantly low immune 
responses to rKLO8 (Fig.5C and 5D). The influence of antibody titres on 
diagnostic test results has been recently shown with rK39. Quinnell et al., (2013) 
have reported a strong positive association between positive signal in rK39 
ELISA and positivity of rK39 rapid test. Results also show that the rKLO8 ELISA 
is more sensitive than DAT (94.3%) and rK39 strip test (81.1%), confirming the 
low sensitivity of rK39 strip test in Sudan. Due to its increased reactivity, rKLO8 
provides enhanced sensitivity for sera VL with low antibody titres. Thus, 
formulation of this antigen in a rapid test may improve field diagnosis of VL as 
compared to available tests.  
 
4- DISCUSSION 
 
 84 
An ideal diagnostic test should identify all positive sera without cross reacting with 
negative sera. The data show that none of the serological test used was able to 
detect all VL cases from Sudan, demonstrating the complexity of diagnosis. Only 
the combination of rKLO8 ELISA and DAT resulted in 100% diagnostic sensitivity. 
Combining results of different tests has been suggested to overcome the problem 
of low sensitivity in East Africa (Cunningham et al., 2012). As sera of VL patients 
may have different level of specificities to recombinant proteins, combination of 
these antigens in a single test would further improve the diagnosis. Several 
authors suggested that use of synthetic recombinant antigens expressing multiple 
immunodominant B- cell epitopes of L. infantum is essential for improving 
diagnostic performance (Soto et al., 1998; Boarino et al., 2005).  
 
We have to be aware that recently infected individuals have elevated IgM 
responses but not yet mounted an IgG response. Sera of such patients will 
expected to reveal false negative results, if tested in an ELISA based on IgG 
antibody detection. This could partially explain the results of some patients that 
were tested negative in the rKLO8 ELISA and rapid test despite thrir strong 
positivity in DAT, which detects different antibody (sub-) classes. More difficult to 
interpret are those 6 confirmed VL cases which were negative in DAT despite 
having detectable antibody responses to rKLO8. Again, antibody specificities and 
parasite diversity could play a role. As a consequence, specific immune 
responses to Leishmania antigens can be lost completely if tested against 
parasites isolated from different endemic areas (Forgber et al., 2006).  In addition, 
the same authors have shown that there are no uniformly dominant antigens 
targeted by the immune responses of different individuals. Variation of antibody 
reactivity in individual sera against recombinant proteins has also been confirmed 
in animal infection models where antigens of L. infantum were differently 
recognised by sera of hamster infected with the same parasite (Folgueira et al., 
2010).  
 
Low antibody titres of VL sera could be attributed to co-infection with HIV, which 
complicates VL diagnosis. Patients with Leishmania/HIV co-infections are known 
to have reduced immune responses and therefore false negative results can be 
expected (Piarroux et al., 1994; Herrera et al., 1995; Ezra et al., 2010). 
Nevertheless, because sera were obtained already time ago, it was not possible 
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to obtain additional clinical data associated with false negative results. Further, 
differences in antibody levels due to age and nutritional status of patients may 
also influence immune responses in VL (Cunningham et al., 2012).  
 
Prevalence of malaria and other diseases is common in areas also known to be 
endemic for VL (de Beer et al., 1991; van den Bogaart et al., 2012). Studies have 
reported prevalence of VL and malaria co-infections in various countries such as 
Sudan, Uganda, Bangladesh and India (cited in van den Bogaart et al., 2012). 
Therefore, a good test system needs robust discrimination between VL and co-
infections. The results of this study indicate that serum dilutions of 1:800 provide 
optimal specificity and sensitivity for rKLO8. Sera of malaria patients did not give 
positive signal in rKLO8 ELISA. This finding is concordant with our previous 
finding from Sudan, where 100% specificity of VL detection has been shown with 
sera tested at high dilutions of 1:1600 (Abass et al., 2006). Other authors have 
reported cross reactivity to rK39 with sera of malaria and healthy controls from 
endemic and non-endemic areas in Sudan (Veeken et al 2003; Romero et al 
2009; Pattabhi et al., 2010). Cross reactivity may be explained by the homology 
of Leishmania proteins and proteins of other prokaryote (Goto et al 2008). 
However, in the original publication describing rK39, sera of malaria were not 
evaluated (Burns et al 1993). On the other hand, Carvalho and colleagues have 
not shown cross reactions to rK39 using sera of malaria patients from Brazil 
(Carvalho et al 2003). In general, results with low antibody titres should be 
interpreted with caution. Notably, the DAT kit showed no cross reaction with any 
of the control sera tested and thus provides the best specificity.  
 
4.3 Performance of serodiagnostic tests in three major endemic 
regions of VL: 
 
VL diagnosis is complicated by fact that the disease is caused by various 
Leishmania sub-species in different endemic regions, with known genetic 
differences (Dey et al., 2007; Sivakumar et al., 2008; Hamad et al., 2010; 
Srivastava et al., 2011b; Zackay et al., 2013; Bhattacharyya et al., 2013). Despite 
this knowledge, diagnostic tests which are often based on a single antigen are 
used in different endemic countries, with the consequence of suboptimal 
diagnosis in some regions. Therefore, it is essential to develop appropriate 
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species-specific diagnostic tests for different regions. Control of the disease in 
these regions will largely depend on the availability of accurate detection 
systems.  
 
In this study, performance of rKLO8- and rK39 ELISA was compared with two 
rapid tests (rK39 and rKE16) and DAT in 3 endemic regions for VL. In general, 
the performance of rKLO8- and rK39 ELISA was excellent in all regions. Optimal 
sensitivity and specificity have been previously reported for the rK39 ELISA in 
several countries (see Chappuis et al., 2007). The strong immunogenicity of 
rKLO8 and rK39 allows detection of Leishmania-specific antibodies at dilutions as 
high as 1:800 with 100% specificity, with no cross-reactivity against malaria which 
was otherwise observed in Sudan at a lower dilution of 1:100. A sensitivity of 
81.8% for VL diagnosis was achieved even in HIV immunocompromised patients 
from France. Unfortunately, the geographical distribution of VL and HIV is known 
to overlap in many areas (Alver et al., 1997b).  Co-infection should therefore be 
taken into account when interpreting results of serological tests (Piarroux et al., 
1994; Medrano et al, 1998).  
 
VL sera from the various endemic regions demonstrated different levels of 
reactivity towards rKLO8 and rK39 antigens. Nearly all sera of patients from India 
showed high antibody titres to both recombinant proteins as compared to patients 
from Sudan and France (Fig. 3.8). On the other hand, some of the sera from 
Sudan and India reacted more strongly with rKLO8 as with the rK39. It was not 
surprising that sera of Indian VL patients have strong antibody titres as patients 
infected with homologous L. donovani strains are expected to develop strong 
responses. Strains of L. donovani in India are known to have high homology 
compared to strains in East African countries where a marked heterogeneity has 
been reported (Kuhls et al., 2007; Alam et al., 2009; Hamad et al., 2010). In 
agreement with our results, other authors have detected strong antibody 
responses to rK39 in sera of VL from India (Kumar et al., 2001). Variability of L. 
donovani strains from East Africa might be due to spread of parasites from other 
regions where different parasite populations are endemic or as a result of 
diversification of autochthonous parasites that have been endemic for long time in 
the same area (Gelanew et al., 2011).  
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The results also confirm the variable sensitivity of rK39- and rKE16 rapid tests 
(RTs) in several VL endemic regions (Chappuis et al., 2007; Cunningham et al., 
2012). Although both tests showed high specificity, their sensitivity is only 
moderate in the VL sera with high antibody titres from India, suggesting that high 
titers can compensate for the heterogeneity of rK39 antigen, at least in India. 
Subsequently, VL sera with low antibody titres such as those from Sudan and 
France can only be detect with low sensitivity. This is supported by the previous 
findings wherein Sudanese VL sera with negative rK39 RT results had 
significantly low antibody responses to rKLO8 and rK39. The fact that rK39 RT 
performs very well in India but not in Sudan and France, in combination with the 
high sensitivity of rK39 ELISA in Sudan and France indicates that antibody levels 
rather than test formats, determine the sensitivity for VL diagnosis. The influence 
of antibody level on VL diagnosis is clearly demonstrated by the high DAT 
sensitivity reported in India. Possibly, the use of DAT antigen prepared from a 
Sudanese strain of L. donovani (1S) contributed to its high sensitivity in Sudan. 
Similarly, DAT sensitivity was clearly increased when applying antigens of L. 
donovani originating from the respective areas (Harith et al., 1995). However, a 
DAT kit also based on L. donovani 1S strain from Sudan, showed high sensitivity 
(94-98.5%) in India, Nepal, Ethiopia and Kenya but lower sensitivity in Sudan 
(85.7%) (Cañavate et al., 2011).  
 
The results reflected again the complexity of VL diagnosis in the different regions 
as none of the available tests detected all positives and negative sera from the 
various regions. As discussed before, results of serological tests should be 
interpreted with caution and combination of different test results seems to be 
important (Boelaert et al., 2008; Cunningham et al., 2012). It is also important to 
note that detection of Leishmania in spleen or bone marrow aspirations missed 
several sera of symptomatic cases that showed positive reactivity in all 
serological tests. This also indicates that misdiagnosis of VL can be expected 
even by applying this gold standard test. Due to the absence of an absolute 
diagnostic reference method, it is not uncommon that clinical suspected VL cases 
are confirmed serologically (Harith et al., 1989; Chowdhury et al., 1993; Pizzuto et 
al., 2001; Raguenaud et al., 2007).  
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4.4 Application of rKLO8 ELISA for serodiagnosis of canine VL:  
Dogs play an essential role in the transmission cycle of VL (Ashford, 1996). 
Therefore, effective control strategy of the disease in human should be based on 
controlling canine VL (CVL), ideally through identification and treatment or 
elimination of infected dogs (Palatnil-de-Sousa et al., 2001; Coura-Vital et al., 
2011). Since parasitological examination is invasive and insensitive, 
serodiagnosis is routinely applied for identification of infected dogs (Schallig et al., 
2004; Otranto et al., 2009; Quinnell et al., 2013).  
In this study, the performance of rKLO8 ELISA and DAT was also assessed for 
detection of CVL using sera of parasitologically confirmed cases and healthy 
controls. Although, only few sera were tested, results demonstrate that both 
rKLO8 ELISA and DAT are equally sensitive and specific for detection of CVL, 
implying 100% sensitivity and specificity. However, these findings need further 
confirmation with larger numbers of dogs. It is worth mentioning that some sera of 
symptomatic dogs with negative parasitological results tested positives in both 
rKLO8 ELISA and DAT. Based on clinical symptoms and high prevalence of the 
disease in those regions, our results seem to be acceptable. Considering its high 
sensitivity and absence of cross reactivity, rKLO8 ELISA represents a 
supplementary diagnostic procedure for CVL. 
 
Previous studies on dogs with CVL have demonstrated different diagnostic 
sensitivity levels for the most commonly applied serological tests (Mettler et al., 
2005; Otranto et al., 2009; Quinnell et al., 2013). This difference can also be 
attributed to genetic variability between Leishmania sub-species prevalent in 
these areas. Also as earlier discussed in human, specificity of host antibody 
responses against individual antigens could have played a role (Falqueto et al., 
2009). Other authors have shown variable sensitivity of serodiagnosis during 
different stages of the disease in natural infected dogs, being lower at early 
infection and higher later (Quinnell et al., 2001).  
 
Co-infections of Leishmania parasites and other vector-borne diseases in dogs 
are common in subtropical and tropical regions. As a result, co-infections may 
manipulate classical clinical presentation and thereby complicate diagnosis. 
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Cross reactivity of canine sera with other diseases can give rise to reduced 
specificity. But, serodiagnosis when carefully defined is more sensitive than 
parasitology. A study of cross reactivity in serum samples from dogs infected with 
other parasitic diseases (such as Trypanosoma cruzi and Ehrlichia canis) showed 
that ELISA and IFAT have a higher degree of cross reactivity than DAT 
(Mancianti et al., 1996; Ferreira et al., 2007). The high specificity of DAT has also 
been shown in sera of dogs infected with Babesia or Leptospira (Oskam et al., 
1996).  
The role of dog as the major reservoir for VL necessitates the application of 
accurate tests to identify asymptomatic cases. If not detected, such cases can be 
permanent source of the parasite for phlebotomine sandfly vectors (Molina et al., 
1994). We think that the limited sensitivity of the current serodiagnostic tests for 
detection of asymptomatic carriers is a major limitation for controlling VL. 
Currently, serological methods such IFAT and DAT are commonly applied in 
epidemiological surveys of CVL. Although IFAT is widely used in Mediterranean 
countries, its low sensitivity and subjective interpretation of results are among the 
important limitations (Evans et al., 1990; Reed, 1996; Mettler et al., 2005; Silva et 
al., 2001).  
The results demonstrate that rKLO8 ELISA is better than IFAT for testing of 
asymptomatic L. infantum infected dogs. rKLO8 ELISA detected all IFAT positive 
asymptomatic sera (100%) and most IFAT negative sera (69.2%). This is 
particularly important as 50% of seropositive dogs can be asymptomatic although 
harbouring the parasites and never develop clinical disease through out their life 
(Moreno and Alvar, 2002; Mohebali et al., 2005). These cases may be related to 
high exposure to the parasite and development of protective immunity (Pinelli et 
al., 1994). In fact, using of serological tests for CVL depend on the purpose. A 
high sensitivity is required to identify asymptomatic infected dogs as potential 
carriers of the parasite. Thus, the higher sensitivity of rKLO8 ELISA compared to 
IFAT would be an advantage, suggesting the possibility for detection of early 
cases with low antibody titres. Indeed, a dog with seropositivity should be 
considered an individual which has to be monitored through follow-up 
examinations (Talmi-Frank et al., 2006).   
4- DISCUSSION 
 
 90 
4.5 Conclusion and outlook for future research: 
 
Diagnosis of VL is a complex problem because none of the available tests has 
absolute reliability in the different regions. Marginal antibody titres may result from 
co-infections such as HIV or malaria. Therefore, a good test system needs robust 
discrimination between VL and potential co-infections. The non-availability of an 
absolutely reliable diagnostic test and the presence of substantial numbers of 
asymptomatic VL cases constitute major limitations in effectively controlling the 
disease. The available tests can neither differentiate between active and past 
infections nor between symptomatic and asymptomatic infections. Performance of 
serodiagnosis is dependent on antibody level in individual VL patients as high 
antibody titres can compensate for the heterogeneity of antigens. The sensitivity 
for VL diagnosis can be improved by using antigens of autochthonous 
Leishmania parasites. The increased reactivity of Sudanese VL sera with rKLO8 
makes this antigen a potential candidate for improving diagnosis of VL in Sudan.   
 
 
 
 
 
Based on the conclusion, further studies are needed in the following areas: 
 
i. Since, rKLO8 evidenced potential for detection of VL in cases with low 
antibody titres, it will be important to evaluate its performance in a rapid test 
format for field application.   
 
ii. Because of the marked heterogeneity among stains of L. donovani in East 
Africa and specificity of host immune responses, further analysis of the 
genetic variations in immunodominant epitopes will enable improving 
diagnosis of VL. This can be achieved by developing a synthetic protein 
construct expressing multiple immunodominant epitopes.  
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1- Leishmania donovani strain LO8 immunodominant kinesin-related 
protein KLO8 gene, partial cds 
 
 
6- APPENDIX 
 
 109 
2- Immunodominant kinesin-related protein KLO8, partial [Leishmania 
donovani] 
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3- Sequence alignment of immunodominant repeats of KLO8: 
 
Repeat 1     LEQLLRESEERAGELASQLESTTAAKMSAEQDRENTRAT 39 
Repeat 2     LEQQLRDSEERAAELASQLEATAAAKSSAEQDRENTRAA 39 
Repeat 3     LEQQLRDSEERAAELASQLESTTAAKTSAEQDRENTRAT 39 
Repeat 4     LEQQLRDSEERAAELASQLESTTAAKMSAEQDRENTRAA 39 
Repeat 5     LEQQLLESEERAGELASQLESTTAAKMSAEQDRENTRAA 39 
Repeat 6     LEQQLRDSEERAAELASQLESTTAAKMSAEQDRENTRAT 39 
                   :     .       : :               : 
 
Tandem repeats of KLO8 were performed to show variability in amino acid composition within 
the repeats. Analysis was performed using ClustalW2-Multiple Sequence Alignment 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Conserved amino acids in various repeats were 
highlighted in black and different residues were left unmarked. 
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